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The activation of EphB1 receptors by their membrane bound ligands ephrins in nociceptive 
neurons have been implicated in the onset and maintenance of different types of pain and in side 
effects produced as consequence of prolonged Mor activation. The use of EphB1 blocking reagents 
rescue opioid-induced analgesia suggesting that antagonists targeting EphB1 receptor could 
represent a novel class of analgesics. 
A potential inverse relation between EphB1 and Mor receptors was displayed in a previous 
investigation by Lombardo Sara where showed that the co-administration of Mor and EphB1 
agonists resulted in an occlusion of morphine-mediated p42/44 MAPK phosphorylation.  
Therefore, the aim of the research was elucidated the signaling pathway and mechanism 
responsible for the functional crosstalk triggered by the co-administration of both ligands and at 
the same time developed and tested different EphB1 antagonist peptidomimetics. 
As results: *ephrinB1/EphB1 activation through PI3K signaling pathways blunted p42/44 
activation morphine-mediated and PKC-dependent in SHSY5Y native cells where in addition 
EphB1 signaling activation seems to be the responsible for blocking the capacity of the morphine 
to modulate adenylyl cyclase activity. *SHSY5Y cells induced to PMA differentiation produced 
up regulation of Mor expression and down regulation of EphB1 receptors allowing that morphine 
significantly activate p42/p44 MAPK even when ephrinB1 was co-administered. *Conversely, in 
PMA-differentiated SHSY5Y cells exposed to TNF-α, EphB1 expression was significantly up 
regulated and the morphine failed to increase p42/44 MAPK phosphorylation. * Moreover, were 
found two novel antagonist peptides capable to counteract ephrinB1-Fc-mediated activation of 
p42/p44 MAPK phosphorylation. 
Concluding that when EphB1 is activated morphine no longer triggers PKC-dependent signaling 
events downstream of Mor activation, explaining the reasons why opioid analgesics are less 
effective in the treatment of different pain states. At this regards, novel EphB1 receptor antagonists 






1. Introduccion   
 
 Eph receptors and ephrin ligands 
 
 Functions and classification  
Eph (erythropoyetin—producing hepatocellular carcinoma) receptors, the largest subfamily of receptor 
tyrosine kinases (RTKs), and their membrane bound ephrin ligands are cell surface molecules and  
important mediators of cell–cell communication, that play a fundamental role in cell behavior during 
embryogenesis and adult life 1–7.  Several studies have demonstrated that are involved in important functions 
as: cell shape, adhesion and repulsion, cell positioning and migration; tissue boundary formation during 
somatogenesis; development of the vascular system; tumor invasion and metastasis; immune function; 
hematopoiesis; blood clotting; stem cells development; tissue repair and maintenance; angiogenesis, control 
of tissue morphogenesis and patterning; cell sorting at compartmental boundaries and bone formation. 1,2,8,9 
In nervous system are regulators of axon guidance during development; neural and synaptic plasticity; long 
term potentiation, synaptogenesis, dendritic filopodia motility, and neural crest cell 1,2,5,10,11  
Eph receptors, based on the structure and the ability to bind their membrane attached ephrin ligands, are 
divided into EphA and EphB receptors. In mammals, there are nine members of  EphA class (A1-A8, A10) 
and five members of EphB class (B1-B4, B6) while Ephrins-As (A1-A5) are bound by a 
glycophosphatidylinositol (GPI) anchor, and ephrin-Bs (B1-B3) contain a short intracellular signaling 
domain 5,6,10,11. Furthermore, Ephs and ephrins interact promiscuously within each subclass. Thus cross-
class interactions known are EphA4, interacting with B-type ephrins and ephrin-A5 can activate EphB2 as 








The extracellular region of all Eph receptors consists in highly conserved N- terminal globular domain 
called ligand binding-domain which is necessary for ligand recognition and binding site that mediates 
receptor-ephrin interaction between cells 11,13,14.  
The globular domain is followed by a unique cysteine-rich motif (Cys domain, comprising sushi and 
epidermal growth factor (EGF)-like motifs) and two fibronectin type III motifs, which appear to be involved 
in receptor–receptor dimerization interactions 13 and facilitate clustering of multiple Eph-ephrin complexes 
11,15.  
In the juxtamembrane region, there is a highly conserved motif containing two tyrosine residues, which are 
the major autophosphorylation sites involved in receptor signaling 13,15.  
The tyrosine kinase domain has been proposed to serve as a binding site for activators of the small GTPases, 
which regulate cytoskeletal organization. A conserved region of 60–70 amino acids in the carboxyl-terminal 
tail of the Eph receptors forms a sterile alpha motif (SAM) domain, which has been implicated in receptor 
dimerization and mediates cell–cell initiated signal transduction 13,15.  
Eph receptors also possess a post- synaptic density protein zona occludens (PDZ)-binding domain. This 
domain is important in  the assembly of Eph or ephrin complexes, that allow interactions with other 
regulatory molecules (Figure 1), and in their localization to specific sites within the cell, such as membrane 
raft microdomains and synapses 13,15.  
The EphrinB display an extracellular Eph receptor binding domain, a single-pass transmembrane region, a 
short intracellular domain with several sites for tyrosine and serine phosphorylation, and a C-terminal PDZ-
binding motif 16 which is phosphorylated by Src family kinases upon ephrin stimulation by Eph receptors 
(Figure 1).  
Ephrin-Bs domains include three tyrosine residues enabling the recruitment of Src Homology 2/3 
(SH2/SH3) adaptor proteins, a PDZ binding domain enabling interaction with adaptor-proteins such as 
glutamate receptor interacting protein 1 (GRIP1), a D-domain for interaction with Erk/MAPK, and a Grb4 




Ephrin-As, in contrast, lack a transmembrane domain and are attached to the cell membrane through a GPI-
anchor. Therefore, ephrin-As rely on other receptors and mechanisms to transduce intracellular signals, for 
instance,  p75 neurotrophin receptor (p75NTR) and the TrkB neurotrophin receptor tyrosine kinase have 
been involved in reverse signaling ephrin-A-mediated which is involved in axon guidance 16,18. 
 
 
Figure 1. Structure of Eph receptors and ephrin ligands. Eph and ephrin signaling relies on specific functional domains; on the 
extracellular side, Eph receptor is composed by ligand binding domain (LBD) which binds to the receptor-binding domain (RBD) 
of ephrins, followed by a Cys-rich domain encompassing the sushi and epidermal grown factor (EGF)-like domains, and two 
fibronectin (FN) domains. The intracellular side of Eph receptor is composed of the transmembrane region (TM), the Tyr kinase 
domain (TK), the sterile alpha motif (SAM) and the PDZ domain. EphrinsA class is linked to the membrane via a 
glycosylphosphatidylinositol (GPI) linkage, whereas the B class has a transmembrane domain and an intracellular PDZ domain. 
Eph–ephrin interaction results in phosphorylation of Tyr residues (P) present in the juxtamembrane domain between the TK and 
TM domains, as well as in the TK and SAM domains. The juxtamembrane phosphorylation is required for TK function, which is 
crucial for many Eph signalling-induced biological responses 15.  
 EphB and ephrinB system 
1.1.3.1 Formation and activation  
In contrast, to other tyrosine kinases receptors where receptor dimerization is enough to trigger biological 
activity, Eph receptors need high local density of their ligands and the formation of clusters as pre-requisite 
to form Eph/ephrin signaling assemblies, which in turn induce a precise downstream signaling pathways 






The formation and activation of Eph/ephrin system is considered a multiple-step process where Eph and 
ephrin domains interact with each other. Prior to activation, the Eph receptors are loosely distributed on the 
cell surface and display minimal kinase activity, unless receptor expression levels are considerably elevated 
3. 
Upon cell–cell contact, ligands and receptors bind each other with 1:1 stoichiometry and nanomolar affinity 
20. Eph receptors use two separate interfaces for the assembly of signaling-competent clusters. The first 
step, in the initiation of Eph-mediated signaling, is the recognition and binding of Eph receptors and ligands 
located on closely opposed cell surfaces. This process, knowing as DIMERISATION INTERFACE; 
produce high-affinity dimers that are the predominant form of the complex. 2,20,21 However, is possible that 
residues of   Eph receptor could produce  lower-affinity binding, principally inEphrinB2, wich could lead 
to the association of two homodimers 16. 
The second interface, called as CLUSTERING INTERFACE, is produced within the cys-rich domain of 
the Eph molecules and is responsible for the formation of the higher-order functional tetrameric 2:2 
complexes, in which each receptor interacts with two ligands and each ligand with two receptors (Figure 
2). For instante, Crystallographic studies of the EphB2– ephrinB2 complex reveal a tetrameric complex 
forming a ring-like structure. 2,12,20,21. The existence of these two separate and independent interacting 
interfaces allows the Eph receptors to utilize the so-called ‘seeding’ mechanism for the assembly of clusters  
3. 
Finally, binding of ephrins to the extracellular part of Eph receptors not only activates their cytoplasmic 
tyrosine kinase domain, but also leads to the transduction of a reverse signal into the ephrin-bearing cell 3  
Importantly, the disruption of ephrin–ephrin homodimers and the Eph–ephrin tetramer formation also 
results in a repositioning of the B-ephrin transmembrane and cytoplasmic domains, converting them from 
an inactive to an active configuration 20 
Furthermore, is important point out that ligand-independent signaling can also occur if the receptor 




 Furthermore, Eph assemblies can be independent of ephrin binding for example,  EphA4-ECD (ectodomain 
receptor) can bind  FNIII-domain of a neighboring receptor molecule without the presence of ephrins 3 
 
Figure 2. Eph receptor clustering and activation. The inactive Eph receptor present auto-inhibited conformation, released 
upon phosphorylation and activation. Ephrin binding to one receptor initiates dimerisation into an Eph/ephrin heterotetramer. 
Further clustering is facilitated by receptor–receptor interactions between multiple domains of adjacent Ephs, including co-
clustering of A and B type Ephs 12.  
 
1.1.3.2 Bidirectional signaling  
The binding of ephrin molecules to Eph receptors induces conformational changes in both proteins 13, 
producing modifications of actin cytoskeleton and microtubular organization22. 
A distinguish feature of Eph-ephrin complexes is their ability to generate bidirectional signals that affect 
both the receptor-expressing and ephrin-expressing cells (Figure 3) 11. Eph receptor “forward” signaling 
depends principally on the tyrosine kinase domain, which mediates autophosphorylation of the receptor as 
well as phosphorylation of other proteins and the associations of the receptor with various effector proteins 
23. 
Ephrin-B “reverse” signaling depends on tyrosine phosphorylation of the ephrin cytoplasmic region 
(mediated by Src family kinases and some receptor tyrosine kinases) and on associated proteins.  For 
instance at the level of the nervous system, Eph/ephrin bidirectional signaling is important not only for the 




Finally, Eph proteins and ephrins can simultaneously act as receptors and ligands, leading to bidirectional 
or parallel and antiparallel signaling (Figure 3), depending on the distribution of Ephs and ephrins between 
interacting cells, as well as the direction of signaling in single ephrin–Eph pairs. Ephrins can also induce 
signaling cascades independently of Eph proteins, a mode of signaling that seems to be evolutionarily 
conserved 15.  
Futhermore,  the interaction produced between Eph receptors and ephrin ligands  in  Eph receptors and 
ephrins co-expressed cells,  is called CIS interaction  in which ephrins can attenuate signaling of Eph 
receptors (Figure 2), for instance in nervous system Cis interaction allow the cell to precisely control the 
axonal trajectory 25,26; whereas TRANS interaction (Figure 2) is produced between neigboring cells, 
facilitate forward signaling and, depending on the identity of Eph receptors and ephrins involved, serve as 
either repulsive or attractant cues for axonal guidance 25. 
 
Figure 3. Eph–ephrin signaling. Forward signaling involves signal transduction from ephrins to Ephs; reverse signalling involves 
signalling from Ephs to ephrins; and bidirectional signaling involves the simultaneous activation of pathways downstream of 
ephrins and Ephs. Parallel signaling occurs when ephrins and Ephs are expressed on the same cell. Anti-parallel signalling is a 
special case of simultaneously occurring forward signalling, whereby ephrin–Eph signals are propagated in both directions 15.  
 
 Forward signaling 
The classic mode of forward signaling is from ephrins to Ephs and frequently results in cell retraction. This 







The signaling is initiated by autophosphorylation and Src family kinases-mediated phosphorylation of the 
intracellular tyrosine residues, resulting in the activation of the tyrosine kinase catalytic domain 16. However 
the interactions also can be kinase independent, for example, EphB receptor in kinase independent 
mechanism plays essential roles in retina axon path finding 28. Furthermore, Ephs can be negatively 
regulated by several protein tyrosine phosphatases and by ubiquitin ligase-mediated internalization and 
degradation 6. 
Once the Eph receptors are phosphorylated, scaffold and adaptor proteins are activated. The adaptor 
proteins, containing Src-homology 2 (SH2) and Src-homology (SH3) domains, can bind and initiate 
phosphorylation of downstream substrates and allow protein–protein interactions, via SAM and PDZ-
binding motifs, for contribute to signaling 16,29. 
Forward signaling is involved in the activation of several cytoplasmic downstream signaling pathways such 
as Src family kinases, mitogen- activated protein kinase, p-21 activated kinase, chemokine pathways, 
heterotrimeric G-protein pathways, and integrin-mediated pathways (Figure 4) 1.  
For each pathway to be activated, the recruitment of adaptor and scaffold proteins are necessary. Adaptor 
proteins involved in forward signaling are: Rho GTPase activating proteins (GAPs) (including RhoA, 
Cdc42, and Rac) which are involved in the regulation of the actin cytoskeleton and cell shape, movement, 
and adhesion 16, guanine nucleotide exchange factors (GEFs) (including ephexins, Vav2, Vav3 protein) 15; 
ADAM10 family proteases 26; non-catalytic regions of Tyr kinase adaptor protein 1 (Nck1) and Nck2 29 
and phosphoinositide 3-kinase (PI3K) (FIGURE 4) 15 which can be suppressed by forward signaling, 
blocking the activation of  Akt - mTORC1 pathway 23. 
GAPs and GEFs proteins are involved in Eph/ephrin mediated axon guidance events 26, among them α2-
chimaerin, which is essential for axon guidance-dependent of EphA4 11, and ephexin induce cytoskeletal 
collapse in growth cone regions exposed to ephrins. Principally, ephexin is essential for both normal axon 
outgrowth and ephrin-dependent axon repulsion in LMC neuron, modulating motor axon pathfinding at 




Furthermore, GTPases protein specifically H-Ras family protein activates a MAP kinase cascade 
culminating in the phosphorylation and activation of the Erk1/Erk2 MAP kinases (Figure 4). This pathway 
Ras-MAP kinase is important in cell migration neurite outgrowth and axon guidance 30, for instance, in 
cultured mouse mesenchymal cells, ephrin-B1-EphB signaling activates Erk to promote proliferation and 
regulate immediate early gene transcription as well as increase cell migration in  P19 embryonal carcinoma 
cells and microvascular endothelial cells by the recruitment of the adaptors Shc and Grb2 to activate H-Ras 
in ephrinB- EphB1signaling 23. 
Vav family GEFs and ADAM10 family proteases are other kind of adaptor protein which have been 
proposed to mediate later events in the ephrin-Eph signaling cascade, enhancing endocytosis and 
proteolysis, which are essential for efficient cell detachment and a complete guidance response and receptor 
activation 7,26  
EphB1, EphB2, EphA2, EphA3 and EphA4 receptors are associated with Nck family protein which has 
been implicated in the organization of actin cytoskeleton, cell movement, and axon guidance due to SH2 
and SH3 domain. For example, SH2 domain of Nck can bind with the first tyrosine residue localized in the 
juxtamembrane region of EphB1, while its SH3 domains bind proline-rich motifs on downstream target 
proteins, one of this is paxillin protein 29. 
Cask-interactive proteins (Caskins) is a scaffold protein expressed in neurons and involved in the regulation 
of synaptic function. EphB1 receptor can form a complex with Caskin1 through the adaptor protein Nck 






Figure 4. Downstream molecules activated in forward signaling (ephrin-Eph) and reverse signaling (Eph-ephrin)31. 
 Reverse signaling  
Ephrin reverse signaling, which generally promotes adhesion 27, is also activated following interaction with 
Eph receptors (Figure 4).  
The ephrin-A proteins are localized in lipid rafts, a specific microdomain of the plasma membrane 28, due 
to the lack an enzymatic domain 23. The lipid raft provides a platform which allows ephrin-A to be 
constitutively associated and transduce reverse signals by interacting with other similarly localized 
molecules 28, for example Ephrin A signaling can be initiated when the glycosyl phosphatidylinositol–





Ret receptor tyrosine kinases 32 as well as the Src-family kinase Fyn and Rho family small GTPases that 
lead to tyrosine phosphorylation of raft membrane proteins, which eventually brings about cytoskeletal 
rearrangement 28.  
Futhermore, Ephrin-As to interact with the EphA or in some cases with EphB2 receptors, can interact in cis 
mode with other co-expressed membrane-associated molecules. This action interactions may help in the 
transduction of reverse signals.  
Integrins are the principal molecules which interact with ephrin-A in cis mode. Integrins are transmembrane 
molecules with many subtypes that mediate adhesion through interactions with the extracellular matrix. 
Some studies have seen that β1-integrin can interact with ephrin-A5 in the lipid raft and help mediate 
reverse signaling driven cell adhesion upon engagement with EphA receptor. This interaction is sufficient 
to sustain neurite outgrowth in retinal ganglion neurons  28. 
Ephrin-Bs structurally have an extracellular domain, a transmembrane domain and a cytoplasmic domain 
which enables these molecules to interact not only with membrane exposed proteins but also with 
intracellular proteins, which allow them to transduce distinct reverse signals 28. In addition ephrinBs can 
transduce reverse signaling in a tyrosine phosphorylation-dependent or -independent 33manner, as well as 
PDZ-dependent manner 23.  
Reserve signaling have been studied in many biological processes including cell adhesion, migration, and 
gene expressions 7. For example, the phosphorylation of EphrinB ligands provides a docking site for the 
SH2 domain-containing adaptor protein Grb4 6,31, this complex is used as signal transducer and activator of 
transcription STAT3, and subsequent activation of Jak-2-dependent phosphorylation that lead the migration 
to the nucleus, where regulates a variety of target genes 16. Furthermore, EphrinB–Grb4 complex results in 
the activation of focal adhesion kinase (FAK) catalytic activity and recruitment of the G-protein-coupled 
receptor kinase interacting protein (GIT) which is involved in cytoskeleton regulation 16. Another important 
complex formed in reverse EphrinB signaling is Grb4–Pak1–Dock180 wich is implicated in control axon 




Moreover EphrinB1 activation affects cell adhesion and migration in vitro and in vivo by the interaction 
with CNK1 scafoold protein. CNK1 - ephrinB1 complex can promote cell migration through RhoA and 
JNK activity. This finding has demonstrated that the overexpression of EphrinB1 increases cell motility in 
cancer cell lines, however, CNK1 depletion by siRNA, abrogates ephrinB1-mediated cell migration and 
JNK activation. 33 
Finally, Ephrin-Bs can also interact in cis mode with numerous membranes expressed proteins such as 
fibroblast growth factor (FGF) receptor, adhesion molecules integrins, claudins, and connexin playing a 
principal role in cell migration and cell-cell adhesion. For instance, FGF modulates ephrinB1 signaling to 
regulate the positioning of retinal progenitor cells within the definitive eye field 28. 
 Internalization and proteolytic cleavage  
Eph receptor–ephrin binding can also lead to endocytosis, proteolytic cleavage, or both, generating 
intracellular Eph/ephrin fragments with distinctive signaling abilities and often leading to proteosomal or 
lysosomal degradation and signal termination 32. For the attenuation, termination and remotion of 
Eph/ephrin, the complex formed from the cell surface can be subjected to endocytosis of vesicles containing 
plasma membrane fragments derived from both cells proteolytic cleavage, by disintegrin, metalloproteinase 
and γ -secretase 1,7,23, and tyrosine phosphatase activity 1.  
In the endocytosis, Eph/ephrin complexes can be internalized into either the Eph receptor- or the ephrin-
expressing cells through the formation of vesicles containing plasma membrane fragments derived from 
both cells 23. The internalization of the receptor-ligand complexes immediately occurred during cell 
retraction. An implication of this unusual mechanism is that the two cells exchange Eph receptors or ephrins 
and possibly their associated proteins, which may continue to signal from intracellular compartments  11. 
For instance, the interactions between EphB1-ephrinB1 induce formation of intracellular vesicles that 
contain the full-length proteins in a complex; the subsequent endocytosis is mediated by a clathrin-
dependent pathway 7,16. The direction of endocytosis depends on the cell type, for example, glial cells are 




Eph–ephrin complexes produced by trans-endocytosis can convert adhesive interactions into cell repulsion 
by activating metalloproteases, such as ADAM (A Disintegrin And Metalloproteases) family members. 
EphB receptors also interact with ADAM10 and E-cadherin. these bindings to ephrin-Bs in trans interaction 
mode provokes shedding of E-cadherin by ADAM10 preferentially in the ephrin-B-expressing cells 23. 
Other proteins activated in trans-endocytosis are Rac-1 and ubiquitin ligase Cbl proteins; the firt one can 
removal adhesive complexes from cell–cell contact sites allowing cell separation and repulsive effects 
whereas the second one can interact with several Eph receptors promoting their ubiquitination 23.  
The major proteins involved proteolityc cleavage of ephrin-Eph signaling are ADAMS; these proteins 
produce cell-cell repulsion that is important for neuronal axon guidance and also for establishment of the 
arterial and venous vascular networks 34. ADAM10 specifically cleaves the A-class ephrins allowing 
termination of EphA signaling 3. When ADAM10 cleave ephrin from the opposing cell, only receptor-
bound ligand is cleaved, breaking the molecular tethers between the opposing cell surfaces, allowing 
internalization of the EphA3/ ephrin-A5 complexes into the Eph-expressing cell. ADAM13 is also reported 
to cleave ephrin-B1 and B2 ligands, and other substrates, including fibronectin (FN) and Cadherin-11 34 
EphBs and ephrin-Bs have also been reported to undergo cleavage by MMPs (Matrix-metalloproteases), 
regulating other MMP functions such as degradation of extracellular matrix facilitating cell migration and 
invasion. In gastric carcinoma cells, silencing of EphA2 expression inhibits cell proliferation, invasion and 
expression of MMP 9 in vitro and in vivo 34.  
On the other hands, Ephrin-B ligands can also undergo metalloprotease/γ-secretase processing following 
binding to EphB receptors 23. Moreover, EphB2 receptor can also be processed by γ-secretase, via both 
ligand dependent and independent pathways. During ligand induced signaling, while the ephrin is 
sequentially processed by metalloprotease and γ-secretase, the receptor ectodomain cleavage occurs in 
endosomes, leads to receptor degradation, and is metalloprotease-independent 34 
Finally, PTPs (Protein tyrosine phosphatases) can also regulate Eph/ephrin signaling and might be 





 EphB/EphrinB system in SNC 
 
Eph receptor and its membrane anchored ligand ephrin are considered key players in earlier and mature 
nervous system 1,4,8, both EphA and B receptors as well as ephrins A and B are expressed in the pre-synaptic 
and post-synaptic neurons as well as in adult olfactory bulb, hippocampus, cerebellum 35 and cortex  24. 
Further their interactions lead to the bidirectional signaling cascades triggering several signaling pathways 
10,36 allowing not only communication between neurons but also between neurons and glial cells 24,35 
specifically with astrocytes 18.  
In the earlier nervous system Eph and ephrin are higher expressed, while in mature adult system are 
expressed at lower levels, but can be up-regulated after neural injury on different cell types as astrocytes, 
neurons and oligodendrocytes 13.  
During the last decade, several studies have demonstrated that the activation of Eph receptors in a kinase- 
independent or dependent manner are involved in different process at  nervous system level, for instance, 
in axon guidance 13, early excitatory synaptogenesis 8 and then later coordinate synaptic function principally 
synapsis plasticity 36 during learning, memory and in response to injuries 31. 
Since several studies have demonstrated that EphB receptors and ephrinB ligands possess a relevant role in 
earlier and mature nervous system, this chapter will be focused in the involvement of EphB/ephrinB system 
in SNC.  
 EphB/EphrinB system in early SNC 
The capacity of  Ephs and ephrins to act in  communications processes of over short distances, such as cell–
cell contact, 3,27 and in adhesive and repulsive responses between interacting cells 6 have suggested that this 
system is involved in nervous system development.  
Both forward and reverse signaling of EphB receptors and ephrinB ligands have been involved in the 
establishment of neuronal connectivity guiding axons to the appropriate targets (axon pathfinding), 




migration of neural progenitors 15, topographic maps, spine morphogenesis  17, and regulation of neural tube 
closure 15  
Furthermore, in the developing of nervous system, repulsive interactions between Eph receptors and their 
ligands are required in diverse areas, including anterior commissure formation, spinal cord, motor neuron 
and neural crest cell migration 13, allowing the interactions between pre-synaptic terminals and postsynaptic 
sites 6. 
In synaptogenesis 18,28 and dendritic spine morphogenesis 17,24,35, the three class of EphB receptors are 
essential in the formation of up to 40% of excitatory synapses in the developing hippocampus and cortex 
35,37. Principally, EphB2 has been considered as indispensable in the maturation of the pre- and postsynaptic 
sides of excitatory synapses, in  fact, EphB2 activation  is sufficient to promote the assembly of presynaptic 
structures even in non-neuronal cells 11. Moreover, Lai and collaborators observed that in triple knockout 
mice (TKO) (lacking EphB1/B2/B3) fewer synapses were formed producing a failiture in the formation of 
dendritic spines in the hippocampus 10, suggesting that ephrin-B/EphB signaling promotes spine formation 
and maturation 13 
EphB2 receptor in kinase activity manner can interact, clusterize and endocytositade others receptors which 
in turn are important in excitatory synapsis, such as NMDA and AMPA neurotransmitter receptors11. 
Likewise, ephrin B by PDZ-binding domain can interact with post-synaptic PDZ domain-containing 
proteins 10 allowing bind syntenin-1 in synaptogenesis 17 and growth-factor-receptor-bound protein 4 (Grb4) 
in cytoskeletal remodeling. 7 
EphB receptors and ephrinB ligands are expressed at synaptic terminals of hippocampal, cortical neurons, 
and presynaptic astrocyte 18. During synapse formation in cortical and hippocampal neurons, forward 
signaling of presynaptic ephrinB2 trigger activation of postsynaptic EphB2 receptors which directly 
interacts with NMDA receptor, activating Ca2+ influx and gene expression promoting dendritic spine 
morphogenesis  10,11,15,18 
Forward signaling ephrinB1/EphB also triggers the activation of Rho family GTPases among them Cdc 42, 




GDP for GTP and thereby activate Rac1 activity which promotes actin cytoskeleton rearrangement 
(FIGURE 5) 10. The activation of Rac1 also acts on PAK (p21 activated kinase) promoting spine formation, 
maturation and synapse formation (Figure 5) 10,24,38 ,as well as, the ubiquitination and degradation of  Rho-
GEF Ephexin5 promotes synapse formation, however, the reduction  of RhoA activity do not  show effects 
on spine morphology 23 indicating a negative regulation in excitatory synapse 7.  
Furthermore, EphB forward signaling can phosphorylate focal adhesion kinase FAK 24 and heparin sulphate 
proteoglycan syndecan-2 38, which interacts with the synaptic PDZ domain protein caskin and promotes 
spine maturation 24,25. Specifically, EphB1 receptor can form a complex with Caskin1, through the adaptor 
protein Nck by its tyrosine 594, to bind  SH2 domain, while its SH3 domains may interact with paxillin and 
Nck-interacting kinase (NIK) participating in the regulation of actin cytoskeleton 29.   In addition, EphB1 
receptor has been considered as axonal adhesion molecule due to in forward and reverse signaling can 
regulate cell adhesion by controlling integrin β1 activation in oligodendrocytes (Figure 5) which have a 
positive effect on the ability of the oligodendrocytes to extend myelin sheets 39. 
Reverse signaling has also been involved on axon pruning, synapse formation and dendritic spine 
morphogenesis in the developing mouse hippocampus through the phosphorylation  of adaptor protein Grb4 
23,40 as well as in morphological and functional maturation of developing retinotectal synapses in the 
Xenopus optic tectum due to the activation of ephrin-B by postsynaptic EphB2 receptor 11. 
Presynaptic ephrin B1 and ephrinB2 with postsynaptic EphB2 are also necessary in synaptogenesis, in fact 
reverse signaling allow the formation of normal synapsis due to the interaction with syntenin-1 17 whereas, 
Ephrin-B3 interact with GRIP1, PICK1 and syntenin-1 proteins regulating the synapse and spine formation 
in the hippocampus and cortex  (Figure 5) 17. 
Other important process, in earlier nervous system, in which ephrinB/EphB system has been involved is 
axon guidance. EphrinB and EphB have the capacity of guide long-distance axonal growth cones. Different  
studies in mice have demonstrated that the ubiquitous replacement of the intracellular domain of EphB1 
and EphB2 by β-galactosidase, mirrors the phenotype of loss of function of the gene encoding ephrin-B1 




connections between the thalamus and the cortex depends on forward signaling 15. Furthermore, EphB1 
expression is sufficient for axon repulsion and for the ipsilateral trajectory of retinal axons. 15 
Finally, is important to review the involvement of EphB receptor and ephrinB ligands in other processes in 
early nervous system. For example, in neuronal migration the lack of ephrinB ligands, in Cajal–Retzius 
cells, can elicit defects in this process 15 as well as in neurogenesis EphB1 and ephrin-B3 play an important 
role in migration of neural progenitors in the hippocampus. In fact the lack of EphB1 significantly reduces 
the number of neural progenitors in the hippocampus, prevents migration and organization of neural 
progenitors, and affects other aspects of neurogenesis such as polarity, cell positioning and proliferation 
35,41. Furthermore, EphB receptor can activate β- catenin, independently of Wnt signal, leading to the 
upregulation of proneural gene expression, allowing Ephs to influence transcriptional control of cell fate 27. 
During embryogenesis ephrinBs allowing cell division and cellular differentiation  by the alternatively 
interaction with growth factor receptors, such as the fibroblast growth factor receptor (FGFR), platelet-
derived growth factor receptor (PDFGR), epidermal growth factor receptor (EGFR), and the TIE2 receptor 
7. 
 
Figure 5. EphB and ephrin-B modulate spine and synapse formation. EphB forward signaling via PAK promotes filopodial 
motility. EphB activation by ephrinB-Fc recruits the Rac1 GEF Tiam1 to EphB complexes containing NMDARs. EphBs also 
modulate the activity of the Rho family GTPases by activating the Rho-GEFs kalirin and intersectin, and signal via FAK to 
activate RhoA. EphB1 forward signaling involves recruitment of Cdk5 and activation of ephexin1 and RhoA, which regulates 
actin reorganization. EphrinB reverse signaling may lead to presynaptic differentiation, possibly invo lving the Grb4/GIT1 




 EphB/EphrinB system in adult SNC  
EphB and ephrinB persist in presynaptic and postsynaptic sites in the adult brain principally in regions 
where neuronal circuits continue to be remodeled in response to environmental changes 11 such as 
hippocampus and cerebral cortex 31, specifically, in pyramidal neurons 8,18, primary sensory neurons, spinal 
dorsal horn neurons 42 and astrocytes 36.  
The principal roles of  EphB and ephrinB in the adult brain are the regulation of synaptic transmission and 
morphology, which in turn also are controlled by synaptic glutamate receptor 8,43, synaptic plasticity 31,36 
and  in response to nerve injury 31.   
Forward signaling has a crucial role in synapse formation and synaptic plasticity in the hippocampus, in 
fact, changes in synaptic transmission and neuronal morphology are involved in the modulation of learning  
11,31 and in memory formation 36. 
Long-term potentiation (LTP), long-term depression (LTD) and depotentiation are phenomena 
underlaying  synaptic plasticityinvolved in EphB/ephrinB system 31.  
Thus, forward signaling between ephrinB3 31 and EphB1 42, or EphB2 receptors 13 has been involved  in 
long-term potentiation (LTP). The activation of EphB2 can in turn trigger the modulation of NMDA-
receptor-mediated calcium influx via a Src- family kinase pathway having direct impact on synaptic 
transmission 17,30, in fact, in the mature brain EphBs are required for normal levels of synaptic NMDA 
receptors 37. 
In addition, the activation of mediators as RAC1 guanine exchange factor, T lymphoma invasion 
metastasis-inducing protein 1 (TIAM1) 31, Grb4, Pick1, syntenin 27, MAP kinase and Src family kinases 25 
is indispensable for the formation of dendritic spines and establishment of functional synaptic plasticity 
27,35.  
On the other hand, the structure of ephrinsB play an important role in synaptic plasticity 27 since only PDZ 
domain-binding site of ephrin-B2 is required  in LTP, LTD, depotentiation 11. 
Reverse signaling has also been involved in memory formation due to its importance in synaptic 




Fc in Xenopus retinotectal system, leads to an enhanced transmission by an early increase in the presynaptic 
transmitter release and a delayed postsynaptic glutamate responses 44. Other studies in cultured hippocampal 
neurons have demostrated that the activation of ephrinB by EphB2-Fc promotes spine maturation leading 
to higher proportion of spines with larger spine heads 10. On the contraty has been also observed that 
mutation in ephrinB1, either due to the  lack the cytoplasmic domain or for mutation of the six intracellular 
tyrosine residues, leads to formation of immature filopodia indicating that reverse signaling and tyrosine 
phosphorylation are fundamental in neuronal processes 10,28. Furthermore, upon the activation of ephrinB 
the activation of downstream pathways such as G-protein-coupled receptor kinase-interacting protein 1 
(GIT 1) can regulate synapse formation by the activation of Grb4, in fact, ephrinB/Grb4/ GIT1 complex is 

















 EphB and EphrinB are involved several pathological processes 
Despite that EphA and B receptors have been studied in cancer, inflammation and in neurological deseases, 
during these chapter we will focus only in the role of EphB receptors and ephrinB ligands in these 
pathologies.  
 EphB/EphrinB system in cancer 
Type A and B of receptors and ligands normally act as tumor suppressors, however, in tumor cell 
arepotentially converted into oncogenic proteins 3 being involved in a wide variety of human cancers 45. 
They can affect the growth, migration, and invasion of cancer cells in vitro as well as tumor growth, 
invasiveness, angiogenesis, and metastasis in vivo 36.  
Depending on the activated signaling pathway have been involved in the differents tumorigenic process 11 
for example, Eph forward signaling promotes cell segregation and is considered as tumor suppressors since 
can inhibit oncogenic signaling pathways, such as the HRAS-Erk, PI3 kinase-Akt and Abl-Crk pathways 
23,46, in colorectal, breast, prostate, and skin cancer cells both in vitro and in vivo 11, whereas reverse 
signaling is often tumor promoting, driving neoangiogenesis and invasion 31 
Abnormal expression of EphB1 receptor has been detected in metastatic gastric carcinoma, colorectal 
cancer, ovary serous carcinoma and renal cell carcinoma 47–49 ,as well as, in different brain tumors, 
principally the up-regulation of EphB1expression  in medulloblastomas whereas the down-regultion in 
gliomas 45,47,50. 
Interestingly, depending on the cellular context and whether EphB1 receptor forward signaling is dependent 
or indenpendent of ephrins ligands, EphB1 can act as tumor suppressor or tumor promoter 47.  
Alterations in the expression of EphB1 have been involved in 1.49% of the cases of glioma 35. In 
glioblastoma multiforme (GBM) patients with higher EphB1 expression levels showed longer survival rates 
47. Therefore, the overexpression and ligand-dependent EphB1 signaling can inhibit cell migration and 
invasion upon ephrin-B2 ligand stimulation 35 which is considered as a negative regulator for glioma cell 




Forward signaling ephrinB2/EphB1 activates several adaptor proteins that promotes cell migration, among 
them EphB1 recruits adaptor protein Grb2, p52Shc and Src whereby can activate MAPK/ERK regulating 
events involved in cell motility 51, as well as, can induce tyrosine phosphorylation of paxillin and form 
complex with Grb2, Grb7, integrins, Nck, paxillin, and FAK proteins  in a c-Src-dependent manner 35  
In medulloblastoma EphB1 expression have an important role in radiation resistance and in cell migration. 
EphB1 knockdown Daoy cells have demonstrated that the lack of EphB1 receptor reduces cell growth, 
viability and migration, as well as, the expression of important cell cycle regulators as cyclinE, besides 
increases the percentage of cells in G1 phase and enhancements radiation sensitivity not only in culture 
cells but also in a genetically engineered mouse medulloblastoma model. Therefore EphB1 has been 
considered as therapeutic target 45.  
Furthermore, EphB1can interact with other tyrosine kinases receptors as epidermal growth factor receptor 
(EGFR), contributing to the metastatic behavior of medulloblastoma cells as well as interacts with β1-




Figure 6. EphB1/ephrins signaling in brain tumors. EphB1 upon the stimulation of ephrinB2 activate three signaling pathways. In 
U87 and U251 cell lines, forward signaling ephrinB2/EphB1 supressess cell motility. Whereas, EphB1 expression in 




 EphB/EphrinB system in inflammation  
Eph/ephrin interaction has been involved in the movement of inflammatory cells to the site of infection or 
tissue injury 1 as well as in the disruption of endothelial–epithelial barriers and adhesion of leukocytes to 
endothelial cells 31.  
Principally, EphB/ephrin B system has been involved in the regulation of T cell maturation and 
proinflammatory gene expression 23,53. For instance, an increase in ephrin-B1/EphB1 expression in 
peripheral blood lymphocytes has observed in patients with rheumatoid arthritis, as well as, EphB1/2 and 
ephrin-B1/2 are up-regulated in the intestinal cells of patients with Crohn’s disease 1. 
Furthermore, in animal models of rheumatoid arthritis it has observed that the activation of EphB1 receptor 
by EphrinB1–Fc fusion protein results in an increase of production of TNF-α from lymphocytes and 
stimulation of the release of interleukin-6 from synoviocytes, as well as, an increase in the number of 
peripheral blood lymphocytes migration into the joint enhancing lymphocyte migration 1,31. 
On the other hands, in intestinal epithelial cells the stimulation of ephrin-B1 or B2, by  EphB1-Fc, induced 
pro-inflammatory genes such as cyclooxygenase-2 and monocyte chemotactic protein-1 1, as well as in 
inflammatory bowel disease (IBD) this stimulation is considered as a novel protective mechanism that could 
promote intestinal epithelial wound healing 54 
 EphB/EphrinB system in neuropathologies 
1.3.3.1 Pain 
EphBs receptors and ephrinBs ligands are expressed at lower levels in mature nervous system (Figure 7a), 
but after traumatic or ischemic nervous system injury 1,26,55 and in prolonged MOR activation 56is produced 
an upregulation  in neurons, surrounding astrocytes and oligodendrocytes 13, affecting synaptic remodeling 
and plasticity13, axon sprouting and repair processes 32. Therefore, have been directly involved in the 
mediation of spinal nociceptive information and central sensitization 57, in dorsal root ganglia and in spinal 
dorsal horn neurons 8,58, contributing in sensory abnormalities in persistent pain states 56 and in the 




The mechanisms by which EphB/ephrinB system have been involved in the induction and persistence of 
pain could be principally due to changes in sensory neuron excitability which is produced by an increase in 
the firing of small-diameter sensory neurons that communicate noxious information to the dorsal horn of 
spinal cord and an increase in spinal synaptic plasticity 8,59 after inflammation or injury. Once that 
EphB/ephrinB system is activated can induced peripheral sensitization, which is manifests for hyperalgesia, 
and allodynia that later could produce central sensitization, which is a major cellular mechanism that  
converte acute nociceptive injury in chronic pain states 59.  
Different molecules contribute to the development of peripheral sensitization  inthe EphB/ephrinB system 
activation and the related downstream59 , among them, MAPKs ,such as, ERK1/2, p38, JNK 59 and p-ERK5, 
p-CREB a nuclear transcription factor 60, phosphatidy linositol 3-kinase (PI3K) 61, protein kinase A (PKA) 
62, protein kinase Cγ (PKCγ) 60 and  calpain-1 and caspase-3 63.  
On the other hand, the activation of other kind of receptors have been related with EphB-mediated pain 
states principally N-methyl-D-aspartate receptor (NMDR) and toll-like receptor 4 (TLR4) 9,37. 
Several studies have demonstrated that the induction of hypersensitivity and pain can occur by enhancing 
EphB-dependent effects on NMDAR function 37. Forward signaling of EphB1 and EphB2 receptor have 
been considered as principal regulator of pain processes via NMDA receptors 37 in particular NR2B subunit 
(Figure 7b)43,64. EphrinB can phosphorylate a single tyrosine (p*Y504) in a highly conserved region of the 
fibronectin type III (FN3) domain of  EphB2 receptor, moduling the EphB-NMDAR interaction in cortical 
and spinal cord neurons, enhancing, not only, NMDAR localization 37 but also sensitization of nociception 
in spinal cord synaptic efficiency which is modulated in an NMDR-dependent manner contributing to 
chronic neuropathic and inflammatory pain states 37 mediated via a MAPK–dependent mechanism 1.  
While Toll-like receptor 4 (TLR4) contribute with EphrinB/EphB system in the induction of cancer pain in 
spinal cord 9. 
Although, all EphB receptor are involved in pain processes, recently  EphB1/ephrinB1 system has been 
considered as a principal complex involved in acute inflammatory pain 56, neuropathic pain 58,64,65, cancer 




In a different studies, have been showed that peripheral nerve injury produced thermal hyperalgesia in wild-
type (EphB1+/+) but not in EphB1 receptor homozygous knockout (EphB1-/-) and heterozygous 
knockdown (EphB1+/-) mice, as well as, the hyperexcitability in dorsal root ganglion neurons was 
prevented in EphB1-/- and EphB1+/- mice 69. In addition, in chronically morphine-treated mice, the 
behavioral signs due to morphine administration were diminished in EphB1-/- mice; concluding that EphB1 
receptors are required in physical dependence and tolerance of opiates 69, in the thermal and mechanical 
hyperalgesia and spontaneous pain in a variety of pain models 43,as well, as in microglial activation and in 
the up-regulation of keys proteins involved in pain such as pNR1, pNR2B, pSrc (Tyr418), pERK1/2, p-
p38, p-JNK, pCaMKII, pCREB, pNR2B, c-fos 59,70,71. 
In CCI and formalin pain models have observed that EphrinB1-Fc activate forward signaling of EphBs 
receptors 59. The activation of EphBs by EphrinB1-Fc is fundamental during hyperalgesia and allodynia, 
since induce a dose-dependent increase of spinal Fos protein expression 61 as well as an increase expression 
of NMDA receptor and up-levels of peripheral and spinal phospho-MAPKs (Figure 7c)  59,71. Furthermore, 
the precense of sensitizers molecules as TNFα in injury and/or inflammatory tissue could induce peripheral 
sensitization, which is an important neuronal mechanism underlying primary hyperalgesia at the site of 
injury or inflammation 59. 
Forward signaling between EphB1 postsynaptic receptor expressed in neurons of the spinal cord and 
ephrinBs presynaptic expressed in pain sensory neurons 32 has demonstrated to be critical in the 
development of bone cancer pain (Figure 7d) 70. In rats, tumor cell implantation (TCI) or spinal 
administration of ephrinB2-Fc (an endogenous ligand) can produce bone cancer–related thermal 
hyperalgesia, mechanical allodynia, and bone destruction, as well as, an increment in the expression of 
TLR4 and EphB1 receptors and IL-1β and TNF-α cytokines in astrocytes and microglial cells 9. In addition, 
ephrinB2-Fc increase the phosphorylation of NR1 and NR2B receptors wich in turn also depend on the 
activation of EphB1 70. However, spinal administration of EphB2-Fc can relieve bone cancer pain and 
prevents or reverses pain behaviors, disminishing the activation of astrocytes and microglial cells; TLR4, 




complex, and the subsequent Ca2+-dependent signals 70, and also increasing the activity of matrix 
metalloproteinase (MMP)-2/9 9. 
Concluding that spinal blocking or targeted mutation of EphB1 receptor could contribute in the treating 
bone cancer pain and TLR4 also could be a potential target for preventing or reversing bone cancer pain 
mediated by ephrinB-EphB receptor signaling 9 
In Diabetic neuropathic pain (DNP), streptozotocin (STZ) or alloxan causes significant activation of EphB1 
receptor in the spinal cord, as well as, activation of astrocytes, microglial cells and IL-1β and TNF-α which 
are important in the pathogenesis of DNP 66. However, spinal blocking EphB1 receptor activation can 
relieve DNP in diabetes induced rats by intraperitoneal injection of streptozotocin (STZ) inhibiting 
mechanical allodynia and the activation of the astrocytes, IL-1β and TNF-α in the spinal cord 66, concluding 
that EphB1 receptor activation in the spinal cord is critical to the maintenance, but not in the induction of 
diabetic pain 66. 
Reverse signaling of EphB1 /ephrinB2 in rats can also contribute to retinal ganglion cells (RGC) apoptosis 
with chronic ocular hypertension (COH) in glial and neuronal elements in the retina which was 
accompanied by increased protein levels of phosphorylated Src and GluA2. High expression of EphrinB1 
and EphB1 in monkeys have also been observed in mild-to-moderate glaucoma, as well as, in cultured 
astrocytes obtained from human glaucamatous patients, concluding that the upregulation of ephrinB/EphB 
signaling in the retina may be common in experimental and clinical glaucoma considering that attenuation 
of EphB/ ephrin B reverse signaling could be an appropriate way for preven the loss of RCGs in glaucoma 
68. 
On the other hand, the Opiates drugs are used in the treatment of moderate-to-severe post-operative and 
chronic pain, however, when opiates are administered simultaneously can activate the nocuous mechanism 
of a sensitization process causing pain hypersensitivity 57. The involvement of EphB1 receptors in these 
processes have been observed in animal models which the scalating morphine treatment 70 and continuing 
infusion of remifentanil 57 significantly up-regulates expression of EphB1 receptor. In a rat hindpaw 




57,70, whereas intrathecal administration of EphB2-Fc, used as a blocking reagent, revert the behavioral 
symptoms and neurochemical signs associated with chronic opiates treatment 70, as well as, reduce the 
levels of pNR2B, pERK and pCREB in the SC 67,69. 
 
  
Figure 7. Involvement of ephrinB/EphB in neuropathic pain. a) low expression of ephrin-B and EphB1 in physiological pain 
conditions. b) In pathological central pain, both ephrin-Bs and EphB1 are upregulated. Activation of EphBs leads to recruitment 
and activation of Src and consequently NMDARs phosphorylation with an increasing of calcium influx leading to c-fos and CREB 
gene transcription. c) Pathological peripheral pain, shares with pathological central pain the activation of EphB and NMDR 
receptors, then the activation of other three signaling pathways caractherize this pain model. Src phosphorylates CamKII, which 
phosphorylates CREB causing nuclear translocation and Cyclic AMP Response Element (CRE) gene transcription. The activation 
of PI3K signaling pathway, which phosphorylates Akt and ERK proteins and consequently translocates to the nucleus to activate 
c-fos gene transcription; and JNK phosphorylated and activated can phosphorylate p-38 and converges to activate ERK. d) in 
Pathological cancer-induced pain shares the principal caractheristic of pathological central and peripheral pain. However, in cancer 
pain the phosphorylation of ERK directly by src kinase to activate gene transcription of c-fos and the up- regulation of   
inflammatory cytokines as TNFα, IL-6, and IL-1β can lead to hyperalgesia, and hyperexcitability of nerve afferents  8. 
 
1.3.3.2 Neurodegenerative diseases  
Aberrant synaptic activity is considered as a major pathological hallmark in neurodegenerative and 
psychiatric disorders 4. Eph receptor and ephrin ligand are present in the development of the central nervous 




regulating synapse formation maintenance and plasticity 4 which are important in learning, memory 
formation and consequently in normal cognitive function.  
Since, Ephs and ephrins play an important role in synaptic efficacy, regulating presynaptic transmitter 
release, postsynaptic glutamate receptor conductance and trafficking, synaptic glutamate reuptake, and 
dendritic spine morphogenesis 5,10,17, their deregulation have been directly involved in aberrant synaptic 
functions associated with cognitive impairment and in long-term memory formation, which can produce 
alterations of synaptic efficacy modifying neural transmission and morphology 36, producing brain disorders 
and diseases with memory impairment symptoms including trauma, stroke, epilepsy, psychiatric, anxiety 
and neurodegenerative diseases as Alzheimer disease, Parkinson disease and Amyotrophic lateral sclerosis 
(ALS) 18. 
Furthermore, various Eph receptors and their ligands have been involved in  the excitatory synapses in the 
hippocampus, including EphA4, EphB1, EphB2, EphB3, ephrinB2 and ephrinB3 4. EphB receptors can 
coordinate synapses due to a multiple upstream molecules, such as,  Rho-GTPases GEFs (guanine-
nucleotide exchanging factor) and GAPs (GTPase-activating proteins) 4. In fact, they regulate actin 
cytoskeleton network through activation of GEF kalirin, intersectin or Tiam1-mediated activation of the 
Rho GTPases Rac1 and Cdc42 4. In addition, EphB2 can regulate the function of post- synaptic 
neurotransmitter receptors as NMDAR by the formation of co-clustering of NMDA receptor and specific 
postsynaptic proteins including calcium/calmodulin-dependent protein kinase II (CaMKII) and Grb1 4. 
Severe or sustained stress can result in changes of synaptic plasticity which can lead to behavioral changes 
associated with fear and anxiety disorders. The effects of EphB2 in NMDAR activation allow to think that 
EphB receptor plays an important role in bipolar disorder and cognitive functions 8.  
Deficiency in serine protease neuropsin, an important protein expressed in amygdala and hippocampus,  has 
been also involved in bipolar disorder and cognitive functions 72. EphB2 and neuropsin are upregulated 
after stress in amygdala which results in cleavage of the EphB2 ectodomain 73. Neuropsin-dependent 




in NMDAR currents observed in neuropsin null mice 73 suggesting that targeting neuropsin-dependent 
cleavage of EphB2 is a potential strategy for treating stress-related and anxiety disorders 8. 
Alzheimer's disease (AD) is considering a devastating disease in which is produced a permanent loss of 
memory and other cognitive functions causing progressive loss of synapses and neurons  32. Senile plaques 
are a hallmark of AD, which are produced by proteolysis of amyloid precursor protein by the presenilin/γ-
secretase intramembrane protease complex, generating the cytotoxic β amyloid (Aβ) peptides 32. Soluble 
Aβ oligomers can decrease NMDA receptors affecting their equilibrium and activity at synaptic sites 
producing impairs synaptic plasticity and glutamatergic transmission (Figure 8) 74.  
In mice models have demonstrated that beta-amyloid (Aβ) directly binds to the fibronectin repeats domains 
of EphB2 affecting its function and increasing its proteasomal degradation 74. The reduction of hippocampal 
EphB2 levels produce memory impairment in early stages of AD due to a decreases of  NMDA surface 
expression with a defective neuronal activation and reduction of LTP (Figure 8) 25. However, since EphB2 
expression levels can regulate the amount of NMDARs at synapses, the overexpression of EphB2 acts as a 
neuroprotector in hippocampal 74.  
The involvement of Ephs an ephrins in neurogenesis suggests that could be used in the treatment of 
Parkinson’s disease 75 which is other type of neurodegenerative disorder characterized by a deep loss of 
dopaminergic neurons in the Substantia Nigra pars compacta (SNc) accompanied by filamentous protein 
inclusions termed Lewy bodies (LBs) in the surviving neurons 76. Jing and collaborators have demonstrated 
that the activation of EphA receptor in lateral ventricle by soluble form of the ephrin-A1 ligand (ephrin-A1 
Fc) could promote regeneration of the brain dopaminergic neurons 75 
The involvement of EphB1/ ephrinB1 system in Amyotrophic lateral sclerosis (ALS), a fatal disease 
characterized by a progressive degeneration of motor neurons that produce the breakdown of neuron-glia 
communication and neuronal dysfunction and death 77, is due to the capacity of EphB1 receptor to produce 
the activation of protective phenotype of astrocytes in human and mouse ALS models77. EphB1 receptor is 




of transcription-3) activation which can regulate astrocyte activation 78, producing astrocyte transformation 
and consequently protective, anti-inflammatory or immunomodulatory pathways 77.  
 
Figure 8. EphBs in AD. The EphB2-Aβ interaction inhibits receptor activation and causes internalization and degradation of both 
EphBs and NMDARs. Degradation of EphB receptors inhibits their ability to retain NMDARs on the membrane potentially though 
the EphB-NMDAR interaction. Fewer NMDARs on the cell surface leads to decreased calcium influx and none of the changes in 















 Interactions between Eph/ephrin system with other receptors 
The activation of Eph and ephrin proteins can produce a cross-regulation with other communication 
pathways producing molecular, functional, and genetic interactions with different cell surface signaling 
pathways controlling broaden range of function in vivo as cell survival, migration and differentiation 3,31,79. 
Eph/ephrins can produce crosstalk with different cell surface receptor (tyrosine kinases receptors and g-
coupled receptor), adhesion molecules, (integrins, claudins and cadherins) and ionotropic receptor (NMDA 
and AMPA receptors) (Figure 9)79.  
Despite, this chapter will be focalized principally in the interaction of Eph/ephrin system with cell surface 
receptor as ionotropic, tyrosine and g-coupled receptor and their different downstream molecules that are 
activated, I have believed interesting also review the interactions formed between Eph/ephrin system with 
other proteins.  
Eph receptor can attenuate Ras-MAP- Kinase signaling downstream of other receptors, such as, integrins 
80,81 affecting integrin-mediated cell communication with the extracellular environment 11. Endogenous 
ephrin-B2 expressed in melanoma cells is associated with β1-integrins and their interaction can promote 
cell adhesion and migration, suggesting a role in tumor progression 11.   
PI3K–AKT signaling has been involved in Eph kinase-independent activities and in cell migration in vitro 
and in vivo. However, in phosphatase and tensin homologue (PTEN)-deficient tumour cells, in which AKT 
and mTOR are active, the expression of EphA2 can suppres AKT phosphorylation and cell migration 31 
Crosstalk between EphB/ephrin-B and Wnt signaling has also been reported. Both EphB receptors and B-
type ephrins produce their signal through components of the noncanonical Wnt pathway  11. This interaction 
produce endocytic removal of EphB receptors from the cell surface, whereas canonical Wnt signaling 
increase EphB transcripts and decrease ephrin-B transcripts 11, for instance, in intestinal crypts an increasing 
WNT expression can induce EphB2 and EphB3 expression while represses ephrin B1 and ephrin B2 




Eph receptor expression and ephrin-dependent activation, in cell-surface localization, can also be regulated 
by E-cadherin. E-cadherin can be drive to the cell surface by EphB signaling thus promoting the formation 
of epithelial adherents junctions and enabling EphB/ephrin-B-dependent cell sorting 11 which is important 
during vascular and neural remodeling 12. In addition adherent junction can be disturb when EphB-ephrin-
B binding is inhibited11. 
Croostalk between EphA2 or ephrin-B1 with claudins has been implicated in the regulation of cell adhesion 
and intercellular permeability. Furthermore, claudins can activate ephrin-B1 tyrosine phosphorylation 
independently of EphB receptors 11.  
Besides, EphBs may also interact with acetylcholine receptors (nAChRs) regulating neurotransmitter 
receptor function 8, in addition, since EphB2 can interact with TNF-α could be considered as  neuroprotector 
82. 
 




 Ion channels receptors  
1.4.1.1 NMDR  
Previously have seen that the interaction between NMDRs and EphBs receptors contribute in  pathological 
states such as long-lasting mechanical hypersensitivity,37 in different pain states, 1 opiate dependence and 
tolerance 57,as well as, anxiety disorders and Alzheimer's disease8.  
Therefore, during this chapter, a summary of how the cross-communitation between both receptor is 
produced will be reported. 
N-methyl-D-aspartate receptors (NMDARs) are essential in synapses 11. Sinaptic localization, function and 
signaling of NMDARs can be regulated by intracellular scaffolding proteins (PSD-95), extracellular 
interacting proteins (neuroligin-1) and EphB receptors. In this way, crosstalk formed between EphB and 
NMDA receptors can control localization, function, and signaling of NMDARs 37. This interaction have an 
important role in neural plasticity, in adult nervous system, regulating the development of glutamatergic 
synapses 83–85.  
Ephrin-B induce activation of EphB2 or EphB1 receptors 36,86 which by its tyrosine Y504 in the intracellular 
domain interact with the NMDAR 37activating and enhancing  its functions 8. Src family kinases interacting 
with EphB2 11 activates both subunits NR1 and NR2 of NMDARs 83 resulting in Ca2+ influx activation and 
subsequent stimulation of various Ca2+-dependent proteins, such as Ca2+/calmodulin-dependent kinase 
(CaMKII), extracellular signal-regulated kinase (ERK) (Figure 10) 38,69,87 and Grb10 6. Furthermore the 
increase of intracellular calcium in turn promotes proteolytic degradation of EphB2, demonstrating that 






Figure 10. Cross-intercation between EphBs and glutamate receptor. a) After binding ephrin-B ligand, EphBs directly interact with 
NMDARs to regulate their synaptic surface localization and function. After activation, EphBs recruit Src kinase to phosphorylate 
GluN2B subunit at Y1472 tirosine blocking binding of the AP2 complex and clathrin mediated endocytosis. b) EphBs regulate 
AMPAR trafficking through a PDZ-dependent interaction with GRIP1 and indirect interactions with synaptojanin-1 (Stj1), a 
phosphatidylinositol 5′-phosphatase. If an EphB receptor is interacting with GRIP1, kinase activation by ephrin-Bs promotes 
AMPAR insertion into the membrane from the recycling pool. Alternatively, EphB kinase activation by ephrin-Bs can also promote 




Is well known that excitatory synaptic transmission is also mediated by AMPA-type glutamate receptors 
which are cell surface receptor and regulate neuronal activity and intermolecular interactions in synapses  
6. During learning, release of glutamate from presynaptic neurons activates AMPA receptors (AMPARs) 
depolarizing postsynaptic neuron 36. Scaffolding proteins, such as, postsynaptic density protein 95 (PSD-
95) and glutamate receptor-interacting protein 1 (GRIP1), synaptic adhesion molecules, such as, EphBs and 
neuroligins, and epidermal growth factor receptor family (ErbBs) have been involved in these processes 8. 
EphrinB2 and EphB2 have involved in the stabilization and regulations of AMPARs at the cellular 
membrane 36. In cultured neurons, EphB2 and AMPARs can associate their PDZ-adaptor proteins with C-




GRIP1 promotes AMPAR surface retention, in fact, when this interaction does not occur is abolished the 
colocalization of EphB2 and AMPA receptors 4 while PICK1 acts to remove AMPARs from the cell surface 
but this interaction is poor understand 8. Furthermore, EphBs can control AMPAR trafficking by ephrin-B 
and kinase activation of EphB2 receptors 8,23. AMPARs can be internalizate by EphB2 receptors throught 
activation of synaptojanin 1 EphB2 – mediated , this activation is involved in clathrin- mediated endocytosis 
(Figure 10) 8. Besides, reverse signaling EphB/ephrinB2 by the increase of cellular level of 
phosphatidylinositol 4,5-bisphosphate and transferrin uptake can be involved in AMPA glutamate receptor 
endocytosis in hippocampal neurons 74.  
 Cell surface receptors  
1.4.2.1 Crosstalk with others RTKs 
Ephs also have the capacity of interact with other RTKs (tyrosine kinases receptors), in particular with 
erbB/EGFR family members 12, Ryk receptors 86, fibroblast growth factor receptor (FGFR) and platelet-
derived growth factor receptor (PDFGR) 7.  
EGFR can interact ligand- independent with EphA2, EphA3 and EphB4 12. EphA2 is considered as an 
effector to promote cell motility and proliferation even independently of ephrin stimulation 11. Moreover, 
at cell-cell contacts activation can alterate the cellular response to EGFR modulating the vesicular 
trafficking of its receptor 88 and consequently cell migration 12.  
The activation of Eph receptor can trapped EGFR in Rab5-positive early endosomes inhibiting Akt-
dependent vesicular recycling,  alterating the distribution of EGFR activity, wich can suppress EGF-
promoted Akt signaling, thereby inhibiting cell migration 88. 
Fibroblast grown factor (FGFR) and Eph/ephrin signaling pathways present an agonistic relation since 
FGFR and EphA4 can transphosphorylate each other and activate common downstream signaling pathways 
in mammalian cells (Figure 11a) 11,79.  
The activation of EphA4 can promot cell proliferation and migration on FGF 2-mediated cells which are 
accompanied by mitogen-activated protein kinase (MAPK) 79 and Akt phosphorylation 89. Furthermore, 




glioma cell proliferation and migration through promoting the FGFR1 signaling pathway, increasing in turn 
MAPK pathway 89. Therefore, the potentiation of EphA4-FGFR1 complex acts enhancing malignant 
phenotype in gliobastomas 3. 
On the other hand,  also ephrin-B1 can interact with FGFR in cis mode, inducing tyrosine phosphorylation 
of FGFR which in turn inhibited the ability of ephrin-B1 to induce blastomere dissociation 79 
Other cross-interaction between RTKs is produced by vascular endothelial growth factor (VEGF) and 
EphA2 receptors. In bovine retinal endothelial cells, forward signaling ephrin A1/EphA2 receptor can 
inhibit VEGF‐induced phosphorylation of VEGF receptor 2 (VEGFR2), producing a reduction in the 
VEGF‐induced angiogenic cell activity 90 suggesting that the VEGFR activity is dependent of EphA2 
receptor. VEGF can also upregulates the expression of EphA2 in microvascular endothelial cells (HBMEC) 
through the independent activation of PI3K/Akt and ERK1/2 signaling pathways91.  
Furthermore, in mouse and zebrafish models have demonstrated that ephrin-B2 can also interact with VEGF 
signalling pathway, promoting sprouting behaviour and motility in the angiogenic endothelium. Ephrin-B2 
is involved in angiogenic and lymphangiogenic control though the regulation of the internalization and 
signalling activity of VEGFR2 during physiological and pathological angiogenesis 92 
Finally, RYK an atypical RTK receptor has been involved with EphB receptor since both receptors are 
engaged in the regulation of axon guidance and craniofacial development (Figure 11a). In mouse models, 
homozygous deletion of Ryk resulted in craniofacial defects, similar to the observed in Eph-B2/Eph-B3-
deficient embryos. Therefore is thought that Eph receptors could phosphorylate RYK regulating the 
migration of neuroprogenitors 79 
1.4.2.2 Crosstalk with GPCRs 
G- coupled receptors are transmembrane receptors which could form crosstalk with Eph receptors. In fact, 
Eph/ephrin signaling and CXCR4/ SDF-1 signaling can regulate processes involving cell chemotaxis 79. 
Eph receptor and ephrin ligands, as well as, G-protein–coupled receptor CXCR4 and its unique SDF-1 
chemokine ligand can regulate cell movement. The stimulation of EphB2 and EphB4 receptors can 




endothelial cell clustering and activating synergic pathways, as AKT proteins, which regulate endothelial 
movement and morphogenesis of blood vessels (Figure 11a) 93. 
Furthermore, ephrinB cytoplasmic domain can bind to the PDZ-dependent signaling pathway, for instance, 
to PDZ-containing RGS3 protein which is a regulator of G-protein-coupled receptor signaling and a 
scaffold protein PAR-3 16. Ephrin-B reverse signaling can inhibited SDF-1-induced chemotaxis of 
cerebellar granule cells which is  PDZ-RGS3-mediated (Figure 11b)  79.  
Furthermore, the synergic activation of G protein–coupled receptor Kiss1 (Kiss1R) and Eph receptors can 
suppress EGFR vesicular recycling, inhibiting EGF-promoted migration in Pten−/− mouse embryonic 
fibroblasts and in MDA-MB-231 triple-negative breast cancer cells 88. 
 
 
Figure 11. Interactions with cell surface receptors. a) Eph receptors interact with FGFR in agonistic interaction producing cell 
migration; with Ryk receptors the agonistic interaction allows the axon guidance and craniofacial development, whereas the 
interaction with chemokine receptors can regulate chemotaxis. b) Ephrins interact with FGFR in agonistic manner regulating cell 












 Eph receptor as a therapeutic target 
 
Ephs and ephrins play an important role in different pathological conditions, whereby currently are 
considered promising therapeutic target for the development of therapies that can help in the treatment of 
human pathologies 94 without affecting other normal physiological processes in which are required Eph 
receptors 95 
So far, have been developed drugs that agonize or antagonize Ephs/ephrins signaling 36 which are being 
used as anticancer therapeutics modulators of synaptic plasticity and controller of regenerative and 
pathological neoangiogenesis, bone homeostasis and remodeling, immune modulation, glucose 
homeostasis and stem cell biology 31 
Different strategies have been developed to modulate Eph/ephrin signal transduction. For instance, 
recombinant monomeric proteins and chimeric proteins containing the extracellular domain of an Eph 
receptor or ephrin fused to the Fc portion of an antibody (Figure 12) 96 which due to the promiscuity of Eph 
receptor and ephrin ligands are not considered as selective inhibitors of Eph and ephrins 31. Therefore, more 
selective targeting agents have been investigated 96, among them include, peptides that bind ephrin-binding 
pocket of Eph receptors, and small molecules that bind the Eph receptor extracellular or kinase domain 96, 
as well as, biological molecules, such a,s antibodies that can recognize specific extracellular epitopes of 
Ephs and ephrins binding to the ephrin-binding pocket or the ATP-binding pocket and siRNAs, miRNAs 






Figure 12. Eph receptor as a therapeutic target. Forward signaling can be inhibited by kinase inhibitors, whereas Eph forward and 
reverse signaling can be blocked by protein–protein interaction inhibitors (PPIs) including antibodies, peptides or small molecules 
22. 
 Molecules that interfered with EphrinB/EphB signaling  
1.5.1.1 Soluble form of EphB receptors as part of fusion protein  
Fc fusion protein or chimeric protein can block the interactions of Eph and ephrin proteins which are 
upregulated in several pathological processes 31.Recombinant Eph/ephrin ECDs proteins are widely used 
as soluble molecules that can activate or inhibit forward signaling, reverse signaling, or both 32. These ECDs 
molecules can couple with high affinity to the fragment crystallizable (Fc) region of human IgG  69 or 
albumin 32. The  administration of  the extracellular domain of Eph or ephrin ECDs fused to Fc can disrupt 
Eph/Ephrin signaling interaction 1. For instance, after nerve injury or formalin injection 69, the spinal 
administration of EphB1/B2-Fc can induce the downregulation of EphB receptors through the up regulation 
of matrix metalloproteinase and the downregulation of molecular pain inducers 70, alleviating spontaneous 
pain, thermal hyperalgesia, mechanical allodynia and opiate-resistant in rodent models 32,97. While, Ephrin 
ECDs fused to Fc can activate Eph forward signaling, but in some cases also promote Eph degradation 
loosing Eph signaling activities 32. 
In addition, Eph/ephrin Fc proteins can also compete with their endogenous counterpartsreducing their 
signaling ability 32.  
On the ther hand, EphB4 act as a tumor suppressor in colon, breast and prostate cancers whereby have been 




glioma, melanoma and prostate tumours with promising results entering in Phase I clinical trials in patients 
with refractory or metastatic solid tumors 31. 
Recently, have been developed multivalent ephrin ECD bioconjugates with precise geometrical 
configurations which were generated by incorporation into nanostructured biomaterials. These 
nanoparticles can accurately modulate Eph/ephrin oligomerization in target cells and thus signaling output 
32. 
1.5.1.2 Small molecules  
Agonist and antagonist small molecules that targeting Eph receptors bind the ephrin-binding domain and 
the ATP-binding pocket in the Eph kinase domain 96 with a modest binding affinities in the micromolar 
range 96. 
The small molecules development for disrupt Eph/ephrin system are, lithocholic acid (LCA), salicylic acid 
derivatives, polyphenols from green tea and polyphenol metabolites, doxazosin (a clinically used α1-
adrenoceptor antagonist), peptide analogs mimicking ephrin G-H loop 22. 
Lithocholic acid inhibits ephrin binding to both EphA and EphB receptors in biochemical assays, for 
example, with EphA2 behaves as a reversible competitive inhibitor, with a Ki value of ~50 μM 96 preventing 
ephrin-induced EphA2 and EphB4 phosphorylation at a similar concentration  22. Furthermore, LCA also 
can prevent apoptosis in adult cardiomyocites by the inhibition of the kinase activity of EphA2 98. 
Recently, UniPR126 (PCM126) a derivative molecule of LCA have been developed which act as 
antagonists of the EphA2 receptor, since can disrupt EphA2–ephrin-A1 interaction with an IC50 of 2.0 
mM, as well as preventing EphA2 activation and cell retraction in human prostate adenocarcinoma cells 99. 
Futhermore, UniPR139 and UniPR502 molecules derivates of LCA have also been developed which act as 
a competitive and reversible antagonist of all Eph receptors reducing both ephrin-A1 and -B1 binding to 
EphAs and EphBs receptors in low micromolar range. Principally, UniPR139 can inhibit ephrin-A1-
dependent EphA2 activation producing an antiangiogenic effect, inhibiting HUVEC tube formation and 




On the other hand, among the salicylic acid derivatives that have been identified 4-(2,5- dimethyl-1H-
pyrrol-1-yl)-2-hydroxybenzoic acid can inhibit ephrin binding to the EphA2 and EphA4 receptors with 
IC50 of 10 mM in binding assays 96. Other compound obtained was a disalicylic acid furanyl derivative 
which is a noncompetitive inhibitor of the EphA4–ephrin-A5 interaction 22. 
Doxazosin has also been recently identified as a novel small molecule agonist of the EphA2 and EphA4 
receptor which can inhibit the activation of Akt and ERK activities EphA2-dependent in prostate cancer, 
breast cancer and glioma cells suppressing aberrant migration 22. 
1.5.1.3 Peptides  
Agonist and antagonist peptides can also be used in the modulation of Eph/ephrin signaling response with 
high selectivity and binding affinity towards the ligand-binding domain (LBD) of individual Eph 
receptors32,95,101.and as in Eph receptor LBD is extracellular, peptides that bind this domain do not need to 
cross the plasma membrane solving a major problem encountered in the use of peptides that bind to 
intracellular targets 94. 
These peptides contain similarity sequence with 15 amino acid motifs found in the G-H loop of the ephrin-
B ligands which is the region that mediate high- affinity interaction with the EphB receptors 95. 
Although peptides and small molecules can be used with the same purpose, even more, peptides present 
several advantages over small molecules, among them , peptides cover the chemical space between small 
molecules and biologic drugs 102, can bind with high affinity to protein interfaces even in the absence of the 
highly concave pockets preferred by small molecules (being particularly effective in the inhibition of 
protein-protein interactions due to their larger size), and also present low toxicity 94. 
However, peptides can also present some disadvantages, including their potentially poor pharmacokinetic 
parameters and oral bioavailability. Since, for in vivo assays, peptides needs high resistance to plasma 
proteases and persistence in the blood circulation peptides have been bind with unnatural amino acids in 
process as cyclization, PEGylation or inclusion into nanoparticles, obtaining novel peptides with reductive 




Phage display has been the approach used to identify peptides that bind to Eph receptors, which have 
identified a series of dodecameric peptides that target the ligand binding domains of several Eph receptors 
with low micromolar range and with high affinity by a single Eph receptor 2,14,31. 
Furthermore, 3 linear peptides identified contain 2 cysteines (separated by 4 or 7 intervening residues) 
enabling cyclization through formation of a disulfide bond. Cyclic peptides formed are promising class of 
Eph receptor-targeting agents, due to their conformations present higher binding affinity and specificity as 
well as better metabolic stability 94. 
To date, the crystal structures of only 4 peptides in complex with the EphA2, EphA4, EphB2 or EphB4 
LBDs have been solved, revealing that peptides can bind to the ephrin-binding pocket in a variety of 
orientations 94. 
YSA, SWL and derivative peptides are agonists that can promote EphA2 tyrosine phosphorylation as well 
as EphA2 degradation 31,101. 
KYL, VTM, APY peptides are antagonists that can inhibit ephrin-induced EphA4 activation in cultured 
cells and mouse hippocampal slices. Blockage of the EphA4 LBD complex by KYL can inhibit EphA4 
activation by amyloid-β oligomers which are believed to play an important role in the synaptic dysfunction 
and cognitive impairment characteristic of Alzheimer's disease 31. 
Notably 8 of the 13 peptides identified by panning on EphB2 also bound to EphB1, suggesting a particularly 
close similarity between the ephrin binding pocket of both receptors 94. 
However, SNEW antagonist peptide can inhibits selectively ephrin-B2/EphB2 interaction in ELISA assay 
with an IC50 value of 15 μM 95 whereas EWLS antagonist peptide binds selectively to EphB1 inhibiting 
ephrin-B2/EphB1 interaction with an IC50 value of  10 μM 95,103. 
TNYL peptide is the best inhibitor of ephrin-B2/EphB4 signaling, even though its potency was only 50-
150 μM for the biotinylated and non-biotinylated versions. In addition, if RAW sequence in the C-terminal 
extension of TNYL formed TNYL-RAW, peptide increased potency compared to TNYL 31. Furthermore, 
TNYL-RAW peptide possesses very short half-life in cell culture medium and plasma, suggesting high 




40 kDa branched polyethylene glycol (PEG) polymer or nanoparticles, the fusion to the Fc portion of an 
antibody, and the complexation of the biotinylated peptide with streptavidin have been used to inhibit 
peptide degradation and rapid blood clearance 95,96. 
Finally, since EphB2 and EphB4 can promote tumorigenesis by interacting with ephrin-B ligands, the use 
of respective antagonist peptides can block human umbilical vein endothelial (HUVEC) cell retraction 
caused by ephrin-induced activation indicating the ability of the peptides to counteract the cell shape 
changes and anti-migratory effects mediated by the EphB2 and EphB4 receptors, opening the possibility of 
using antagonist peptides for cancer therapy 31. 
1.5.1.4 Kinase inhibitors  
Tyrosine kinases inhibitors (TKI) can bind to the ATP- binding pocket of Eph receptors with nanomolar 
affinity and some of them are being evaluated for their potential effects on oncogenic Eph function 31.  
Inhibitors of EphB4 have been identified, principally NVP-BHG712 molecule, discovered by Novartis , 
and identified by computer design using a model of the EphB4 kinase domain, can inhibit EphB4 
autophosphorylation and vessel formation in vivo after oral administration 32,96. XL647 molecule,other 
tyrosine kinases inhibitor developed by Exelixis, California USA, is a novel second generation ATP-
competitive small-molecule inhibitor of epidermal growth factor receptor (EGFR), ERBB2, VEGFR2 31 
which also can block EphB4 phosphorylation that was reached the clinical Phase II for the treatment of 
non-small-cell lung cancer (NSCLC) with non-favorable results.32 
Dasatinib is other multi-targeted kinase which inhibit EphA2, EphB1, EphB2 and EphB4 kinases and 
reduces EphA2 expression. The second-generation and third-generation of Src and Abl inhibitors nilotinib 
and bosutinib, respectively are other kind of TKIs with in vitro Eph- inhibitory properties which inhibits 
EphB1, EphB2 and EphB4 31 
1.5.1.5 Monoclonal antibodies  
Activating and inhibitory monoclonal antibodies that recognize Eph/ephrin ECDs with high binding affinity 




During the last years have been developed monoclonal antibodies with particular interest on EphA2, 
EphB2, EphB4, and ephrin- B2 which have shown to be efficacy in mouse tumor xenografts as 
antiangiogenic/anticancer agents and in some cases in combited with anti-VEGF therapy 32 
EphA2 was the first Eph to be considered for therapeutic antibody development 31. In a panel of agonistic 
monoclonal antibodies (agonistic mAbs), mAb EA5 was able to reduce microvascular density and tumor 
growth and increase survival in ovarian cancer xenografts 104, as well as, inhibit breast cancer xenograft 
growth and metastasis 105 
Genentech company also developed anti-EphB2 mAb 2H9 which antagonizes EphB2–ephrin B1 
interactions and causes internalization of non-phosphorylated EphB2 in color cancer 106. 
Because of  the essential roles of EphB4 and ephrin B2 in embryonic vasculogenesis and tumor 
angiogenesis, Vasgene (California, USA) and CNIO Biotechnology (Madrid, Spain) developed mAbs for 
this proteins 31. Vasgene’s mAbs caused EphB4 degradation, inhibiting tumor angiogenesis and  growth, 
and, in combination with bevacizumab, caused tumor regression in xenografted mice 107 whereas single-
chain (scFv) anti-ephrin B2 antibodies  reduced tumor growth by inhibiting formation of tumor blood and 
lymphatic vessels 108 
1.5.1.6 siRNAs or antisense oligonucleotides 
Other type of direct therapeutic approach developed for modulate Eph/ephrin system is the regulation of 
the gene expression using small interfering RNA or antisense oligodeoxynucleotides 46 
siRNAs or antisense oligonucleotides have been used for inhibit EphA2 or EphB4 responses. These 
molecules have the capacity of dowregulate the expression of both receptors, inhibiting the malignant cell 
behavior in vitro and tumor growth in vivo 46.  
Delivery of EphA2 siRNA to tumors, using neutral liposomes, inhibits tumor growth and metastasis in 
mouse models of ovarian cancer. Furthermore, EphA2  siRNA can be combined with focal adhesion kinase 
(FAK) or with paclitaxel chemotherapy 109.  
On the other hand, siRNA and antisense oligodeoxynucleotides for targeted knockdown of EphB4 




tumor growth in a murine tumour xenograft model 110. Furthermore, ephrinB2 siRNA has been administered 
in mice model blocking EphB1 receptor and therefore inihibiting neuropathic hyperalgesia and morphine 
dependence 69, as well as, EphB1 siRNA reduced drastically EphB1 receptor in DAOY cell model reducing 
cell migration and enhancing cellular sensitization to radiation therapy 45 
 Eph receptor – binding molecules conjugated in the delivery of drugs, toxins or 
imaging agents  
Because of the high expression of the Eph receptors in many tumors, molecules that bind Eph receptors 
represent attractive targets for the delivery of several molecules to cancer tissue 46 
Several chemotherapeutic drugs, toxins, deliver imaging agents, radioisotopes and nanoparticles have been 
conjugated to Eph or ephrin antibodies and Eph peptides with the aim of cause receptor-mediated 
internalization 32,46. Furthermore, Eph receptors and ephrins could be considered as entry receptors for 
viruses 32. 
Linear and cyclic peptides used with these conjugated molecules can enhance the selective delivery of 
agents to tumors overexpressing specific Eph receptors, as well as, enable tumor visualization for early 
detection and diagnostic purposes, monitor the effectiveness of therapy and image-guided surgery 94.  
EphA2 and EphB4 are principally considered as attractive target for their widespread expression in both 
cancer cells and tumor vasculature 46.  
EphA2-specific YSA agonistic peptide and its derivates were conjugated to paclitaxel through a triazole 
ester linker, enhancing the efficacy of paclitaxel in a PC3 prostate cancer mouse xenograft model without 
signs of toxicity but with poorly bioavility in mouse xenografts 32,94. Furthermore, YSA peptide was fused 
to the homodimer p19 siRNA-binding protein to deliver functional siRNAs inside of ovarian cancer cells 
with high levels of EphA2, leading to siRNA-mediated gene knockdown 94. 
Due to TNYL-RAW peptide possess high binding affinity by EphB4 and slow dissociation rate has been 
well suited for cancer imaging 94.EphB4 antibodies and the high-affinity EphB4-targeting peptide TNYL-




32.EphB4-binding peptide TNYL-RAW was conjugated with polyethylene glycol (PEG) and with 
radioisotopes (Cu)64 to identify EphB4-overexpressing cells in small animal biodistribution 31. Besides, 
64Cu-DOTA-TNYL-RAW, a promising radiotracer for PET-computed tomography (PET-CT) imaging, was 
successfully used to image EphB4-positive PC3 prostate cancer and CT26 colon cancer cells in mouse 
tumor xenografts 94.  
Since, nanoparticles can protect peptides of a rapid degradation and clearance from the blood circulation 94, 
the TNYL-RAW peptide has been conjugated with various nanoparticles for controlled its delivery to 
EphB4-positive cells. TNYL-RAW peptide was conjugated through a PEG linker to hollow gold 
nanospheres which in turn were loaded with the chemotherapeutic drug doxorubicin. After the treatment 
with these molecules can be seen complete regression of most tumors without systemic toxicity. Targeting 
EphB4 with the cTNYL-RAW peptide can enhance laser-controlled chemo photothermal therapy of tumors 
through a single gold nanoparticle delivery system 94. Furthermore, TNYL-RAW peptide conjugated with 
polymeric micellar nanoparticles labelled with the near-infrared dye indocyanine 7 (Cy7)111 allowed 
multimodal whole-body imaging of tumor-bearing mice by single- photon emission computed tomography 
and near- infrared microscopy, being this technique promising for the development of non-invasive 
strategies for visualizing tumor lesions 31. 
Nanoparticles, were also used with YSA peptide which was attached through a PEG linker to polyaspartic 
acid and coated on anisotropic gold nanoparticles (nanorods). This molecule was explored for both aims 
imaging with near infrared light and photothermal cancer therapy 94 
Finally, YSA peptide can be encoded by the adenovirus genome which is considered as a vector for gene 
therapy and vaccination. Due to YSA contains only natural amino acids can bind adenovirus and  
internalized through EphA2 activation, which is promising for adenoviral transduction of EphA2-positive 






 Vaccine based immunotherapy  
The high expression of Eph receptors in tumors have considered the possibility to use  Eph-derived peptides 
as anticancer vaccines  32. EphA2 and EphB6- derived peptides have been tested raising an immune 
response, promoting the activation of cytotoxic T-lymphocytes and destroying glioblastomas 31,32. 
EphB6 peptides can induce cytotoxic T cells activation from human leukocyte antigen A2-positive (HLA-
A2+) in glioma patients whereas EphA2 peptide-pulsed dendritic cell vaccines that induce natural killer, 
CD4+ and CD8+ T cells which inhibit growth and metastasis in mouse EphA2+ tumor models 111,112. 
EphA2 peptide has been studied in phase I/II trial in recurrent glioma, evaluating the safety of and clinical 
response to pulsed dendritic cell vaccination with glioma-associated antigens, demostrating measurable 
CD8+ T cell and clinical responses in 58% of patients. Furthermore, it has been assessed the effect of 
dasatinib on the immune-suppressive tumor microenvironment, in which trigger tumor cell EphA2 
degradation, thereby improving CD8+ T cell recognition of cell surface EphA2 and enhancing the killing 


















2. Aim of the research 
 
Opioid receptors are members of the G protein-coupled receptor (GPCR) family. The most 
important class of opioid receptors in clinic are Mu opioid receptors (MOR), which can be 
activated by both endogenous and exogenous opioids in central and peripheral nervous system, 
where they produce a significant analgesia through different signaling events such as protein-
protein interactions between PKC/PKA and JNK proteins 113 as well as inhibition of adenylyl 
cyclase activity 113  and activation of p42/p44 MAPK phosphorylation 114. 
Morphine and related Mu opioid receptors (MOR) agonists are still among the most widely used 
pain killers, in fact morphine is one of the most prescribed and effective drug used in the treatment 
of acute and chronic pain conditions 115. However, the presence of side effects as the promotion of 
analgesic tolerance, dependence and hyperalgesia 116 by repetitive or prolonged MOR activation,67 
as well as the low effectiveness in chronic pain states which are accompanied by sustained glial 
activation and altered neuron-glia cross-talk,117 limit their use in clinical therapies. 
The cellular and molecular mechanisms involved in these phenomena are complex and may 
implicate several factors, as receptor desensitization 118 or activation of other receptor systems and 
intracellular signaling proteins, as well as neuronal alterations produced by prolonged MOR 
activation or after nerve injury which could activate certain molecules that are important during 
development but are inactivates in matured nervous system.  
On the other hand, the tyrosine kinases Eph receptors and their membrane-anchored ligands 
ephrins are expressed in the nervous system where their interactions normally initiated by cell-cell 




and reverse signaling produced in ligand expressed cells can regulate through neuron-glia 
communication 18 several physiological and pathological functions. 
Physiological functions as modulation of axon guidance, neurogenesis, synaptic transmission, 
synaptogenesis and neuronal migration in developing nervous system 8,13 and synaptic plasticity 
in learning and memory formation in mature nervous system 36 involve Eph/ephrin system. 
Moreover, alterations in Eph/ephrin system, principally type B receptors and ligands, has been 
implicated in different pathological processes as inhibition of neural repair after traumatic injury 
as well as in tolerance and dependence to opiates, and in pain states of different etiology 31 in 
which opioids administration and principally morphine is the major drug therapy used. 
Different conditions as tissue injury, tibia bone cavity tumor cell implantation (TCI) 70 as well as 
different pain models including chronic constriction injury (CCI), dorsal rhizotomy 65, 
carrageenan, formalin 61, L5 distal crush injury 64 and microglial activation following PNL (partial 
sciatic nerve ligation or Seltzer model) 43 have showed the involvement of EphB/ephrin B system 
in the modulation of inflammatory pain, neuropathic pain, diabetic pain and bone cancer pain 66,70. 
Furthermore, in these pain models it has been observed that the expression levels of ephrin-B1, 
ephrin-B2 and EphB1 are upregulated in dorsal root ganglia (DRG) neurons and spinal cord,58,64,65 
where the activation of EphBs receptors (forward signaling) by ephrinBs lead to peripheral 
sensitization characterized by the induction of thermal hyperalgesia and mechanical allodynia 71 
which increase the synaptic plasticity that can induce central sensitization, converting acute 
nociceptive injury in chronic pain states 59.  
During the last years different research groups demonstrated the key role of EphB1 receptor in 
different pain processes; in fact, it has been observed that after nerve injury only wild-type 




activation of EphB1 receptors by ephrinB1-Fc ligand produced a dose- and time-dependent 
thermal and mechanical hyperalgesia accompanied by the up-regulation of PI3K protein and c-Fos 
activation expression 61. Activation of mitogen-activated protein kinases (MAPKs), particularly 
p42/p44 MAPK, which in turn can produce inflammatory cytokines such as IL-1β, IL-6 and TNF-
α 119 was also reported.  
Likewise, chronic morphine or remifentanil exposure significantly up-regulates expression of 
EphB1 receptor and N-methyl-d-aspartate receptor (NMDR) in mouse spinal cord;57,69 therefore, 
EphB signaling has also been involved in the development of opiates dependence, analgesic 
tolerance, hyperalgesia and withdrawal symptoms 116.  
At the moment, EphB receptor blockers as EphB1-Fc or EphB2- fc molecules 56,58 or ephrinB2 
siRNA 64 or targeted mutation of EphB1 receptor (EphB1-/-) 69 have been used with the aiming at 
preventing the effects of EphBs receptors in different pain states as in inflammatory and 
neuropathic pain, 64,69 in order to inhibit spinal activation of MAPKs, in bone cancer pain 119 
induced by tumor cell implantation (TCI) alleviating mechanical allodynia and reducing the 
expression of spinal inflammatory cytokines and in chronic morphine or remifentanil treatment 
57,67abolishing their behavioral symptoms and neurochemical signs; all these findings suggest that 
the modulation of EphB1 signaling could be used as an option for pain treatment and pathological 
processes associated with opiates administration. 
Furthermore, the activation of Eph receptor and ephrin ligands can be dependent and independent 
of each other through the activation of bidirectional signaling or crosstalk with other signaling 
systems respectively. Thus either way leading to the activation of several signaling pathways 
which may be implicated in a vast array of functions 30,46. Different studies have revealed the 




cross-communication between them (transactivation), which is an important pathway where RTKs 
utilize GPCR signaling molecules to transduce signals which is initiated by both and is mediated 
by specific kinase dependent cascades 120. 
Since Lombardo Sara confirmed that EphB1 and MOR activation presented antagonist effects in 
the activation of p42/44 MAPK phosphorylation and considering all above-mentioned findings, 
the aim of the preset research is:  
• To confirm that the activation of EphB1 receptor by ephrinB1-Fc ligand may counteract 
the morphine-mediated activation of p42/p44 MAPK phosphorylation.  
• To elucidate the molecular mechanisms and signaling pathways involved in the functional 
crosstalk between EphB1 and MOR through their effects on p42/p44 MAPK activation. 
• To determine if blocking the pathway involved in the occlusive crosstalk could lead to 
rescue p42/p44 MAPK phosphorylation produced by morphine. 
Finally, to validate the role of EphB1 signaling in the occlusive crosstalk between EphB1 and 
MOR, as a potential pharmacological target considering that it could contribute to the 
ineffectiveness of opioid analgesics and to their side effects. Therefore, the development of 
molecules that can inhibit selectively EphB1 receptor could represent future innovative pain 
therapies.   
Koolper and collaborators,95 in fact, through phage display approaches obtained linear peptides 
sequences for EphB1 receptor antagonists, from which we developed four novel EphB1 
peptidomimetic in order to: 
• Evaluate the capacity of four peptides to block or at least reduce the intracellular signaling 




3. Materials and Methods 
 
 Plasmid and reagents. 
EphB1 (pCMV6-AC-GFP) plasmid was purchased from OriGene Technologies (Rockville, USA). Ephrin 
B1- Fc was obtained from R&D System (Minneapolis, USA) and morphine hydrochloride was from 
Boehringer Ingelheim limited (Bracknell – UK). 
EphB1 (5F10) Mouse mAb monoclonal antibody, anti rabbit-phosho p42/44 MAPK, anti rabbit p42/44 
antibody and phospho-PKC (pan) (βII Ser660) antibodies were purchased from Cell Signaling Technology, 
whereas β-actin polyclonal antibody and peroxidase-conjugated secondary antibodies anti-rabbit or anti-
mouse or anti-goat were purchased from Santa Cruz Biotechnology.  
Cultures media were obtained from Thermo fisher scientific. PP2 (selective inhibitor of Src-family tyrosine 
kinases), Gӧ6983(PKCα/δ/β inhibitors), LY294002 (PI3Kα/δ/β inhibitors), Polyethylenimine branched 
(PEI Transfection Reagent), BSA (bovine serum albumin), TNF – α (tumor necrosis factor), Phorbol 12-
myristate 13-acetate (PMA), and Forskolin were purchased from Sigma (Steinheim, Germany).  
Cayman chemical cyclic AMP Elisa kit were obtained from Chaymanchem Ellsword Rd, Ann Arbor Mi, 
USA.  
[D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin (DAMGO) was purchased from Bachem (Weil-am-Rhein, 
Germany) and [3H]-DAMGO from GE Healthcare (Milan, Italy).  
All other reagents of analytical grade, or of the highest purity available, were purchased from Sigma or 
Roche. 
 Cell culture. 
Human embryonic kidney HEK-293 cells were grown in Eagle’s minimum essential medium (EMEM) 
supplemented with 10% FBS, 1% nonessential amino acids, 1% L-glutamine and 100 U/ml antibiotic-
antimycotic. Human neuroblastoma SHSY5Y cells were cultured in Dulbecco’s Modified Eagle’s Medium 




streptomycin. Cells were grown at 37°C in a humidified atmosphere containing 5% CO2. All cell lines were 
purchased from American Type Culture Collection (ATCC, Rockville, MD, USA). 
  Western Blots analysis in SHSY5Y cell model  
For these experiments, we used SHSY5Y undifferentiated and differentiated cells which endogenously 
expressing both receptors EphB1 and Mor 121; for the differentiation of SHSY5Y cells, we used Phorbol 
12- myristate 13- acetate (PMA) at a concentration of 16 nM for 5 days.  
Furthermore, undifferentiated and differentiated SHSY5Y cells were exposed to TNF-α at a concentration 
of 10ng/ml for 48 hours.  
Hence, during this research we used three different experimental settings: SHSY5Y native cells, PMA-
differentiated SHSY5Y cells and PMA-differentiated SHSY5Y cells exposed to TNF-α. 
For Western blots analisys, SHSY5Y cells in the three states were incubated in serum-free medium for 16–
18 h and subsequently treated with ephrinB1-Fc (EphB1 receptor soluble agonist) at a concentration of 
1μg/ml and/or morphine (Mor agonist) at a concentration of 1μM. Besides, pharmacological tools as PKC, 
Src, PI3K inhibitors were used to selectively inhibit specific signal transducers.   
Total protein lysate was obtained by homogenization cell in MAPK buffer lysis (50mM Tris-Cl, 300mM 
NaCl, 1mM EDTA, 1mM Na3VO4, 1mM NaF, and 10% glycerol) with protease and phosphatase inhibitors 
cocktail. The homogenates were sonicated for 10 seconds (speed 4) and then centrifugates at 17000 g for 
25 minutes at 4°C. The supernatants were collected and protein concentration was measured by BCA assay 
(Pierce); 15μg of total protein lysates were used to analyzed p42/44 MAPK expression, the lysates were 
denaturated at 95°C for 5 min and then loaded and separated by 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis at 20 mA for 4 hr. MagicMark™ XP Western Standard (Invitrogen) 
served as a molecular weight standard. Blots were transferred to nitrocellulose membranes (Whatman, 
Middlesex, UK) for 1.5 hour at 400 mA. Membranes were blocked with 5% BSA-TBST 0,1% for 1 hour 
at 23°C and incubated overnight at 4°C with the following primary antibodies: primary polyclonal rabbit 




4°C. Later membranes were washed 3 x 5 min in TBST 0,1% and incubated with peroxidase conjugated 
secondary antibodies anti-rabbit at a dilution of 1:8000, for 1 hour at 23°C and then were washed for 3×5 
min in TBS-T 0,1%. Membranes were developed and analyzed as a described for Bedini and collaborators 
122.  
The same protocols were performed to determinate changes in protein levels of EphB1 receptor and PKC 
protein, where the total protein lysates were extracted by T-per buffer lysis (Pierce Thermo Fisher 
Scientific) with protease and phosphatase inhibitors cocktail and the homogenates were shaking for 10 
minutes at 4°C and then centrifugates at 10000 g for 10 minutes at 4°C. The supernatants were collected 
and protein concentration was measured as above described. In the case of EphB1 protein were loaded 50 
μg of total protein lysate and separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
whereas for PKC protein were used 15µg of total protein lysates and separated by 12% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis. Membranes were incubated with primary monoclonal mouse 
anti EphB1 (1:1000) or phospho PKC (1:1000) or goat polyclonal anti actin (1:1000) overnight and then 
used anti– mouse or anti-rabbit or anti-goat secondary antibodies respectively.  
 Cells transfection and Western Blot analysis in HEK- 293 cell model.  
HEK-293 cells (no expressing endogenously EphB1 and MOR receptors) 121 were plated in 6-well dishes 
and at 50–60% confluence were transiently transfected with both plasmid EphB1 (1,5 µg/well) using PEI 
Transfection Reagent. HEK-EphB1 cells were cultured in serum-free medium for 16–18 h and then treated 
with EphrinB1-Fc (1μg/ml) and/or different concentration of possible EphB1 antagonist peptides for 15 
minutes. Total protein lysates were obtained by T-per buffer lysis (Pierce Thermo Fisher Scientific) with 
protease and phosphatase inhibitors cocktail and the homogenates were shaking for 10 minutes at 4°C and 
then centrifugates at 10000 g for 10 minutes at 4°C. The supernatants were collected and protein 
concentration was measured by BCA assay (Pierce); 15 μg of total protein lysates were used to analyzed 




 Saturation binding assays 
SH-SY5Y cells (both undifferentiated and differentiated) were used for saturation binding assays, in order 
to quantify MOR receptor protein levels. Cells membranes were prepared by homogenizing cells in 1 M 
Tris–HCl buffer, pH 7.4, containing 0,5 M EDTA, 1 mM dithiothreitol, and 1 mM benzamidine, with a 
Polytron homogenizer. After centrifugation (2000 rpm for 10 min at 4°C), supernatants were centrifuged 
(18 000 g for 30 min at 4°C) and the pellet was resuspended in 1 M Tris–HCl buffer, pH 7.4, containing 5 
mM MgCl2. Protein concentration was determined by BCA assay (Pierce). For saturation binding 
experiments, cells membranes (20µg/tube) were incubated in 100 mM Tris–HCl, pH 7.4, containing 0.3% 
bovine serum albumin with increasing concentrations of [3H]-DAMGO (5-500 nM). Non-specific binding 
was determined in the presence of DAMGO (500µM). After 90 min incubation at 25°C, bound ligand was 
isolated by rapid filtration on Whatman GF/B filters. Filters were previous activated with 0.3% 
polyethylenimine and washed with ice-cold 1M Tris–HCl buffer, pH 7.4, and finally scintillation fluid for 
24 h before counting. Triplicate determinations were made for each experiment. Data were analyzed as 
explained by Bedini and collaborators 123  
 Total RNA preparation and real time-polymerase chain reaction (RT-
PCR) analysis 
Changes in mRNA levels of EphB1 and Mor receptors in SHSY5Y undifferentiated, PMA-differentiated 
or PMA- differentiated cells exposed to TNF- α were evaluated by RT-PCR. Cells were treated and then 
collected and centrifuged (500 g for 5 min) and rinsed with phosphate-buffered saline (PBS). Total cellular 
RNA was extracted using Trizol® reagent (Invitrogen) and digested with RNAse free DNAse (Invitrogen) 
for 15 min at 25 °C according to the manufacturer's instructions; 2 μg sample was reverse-transcribed using 
the High-Capacity cDNA Reverse Transcription Kit™ (Applied Biosystems, Foster City, CA, USA) 
according to the manufacturer’s instructions. RT-PCR was employed for relative quantification of mRNA 




manufacturer's instructions. To amplify EphB1 cDNA, a sense primer (5′-
GACTGACGATGATTACAAGTCAGAGC-3′) and an antisense primer (5′-
AGATGGCCACCAAGGACACA -3′) amplifying a 101bp fragment, producing a fragment (1953-2053bp) 
from GenBank Accession no. NM_004441.4 at 50 µM final concentration. To amplify hMOPr cDNA, a 
sense primer (5’-CTGGGTCAACTTGTCCCACT-3’) and an antisense primer (5’-
TGGAGTAGAGGGCCATGATC-3’) were used at 2.5 nM final concentration for amplifying a 146-bp 
fragment (327–472 bp) from GenBank Accession no. NM_000914.MOR 123. As a control, a 169 bp 
fragment of the L19 ribosomal protein was amplified using a sense primer (5′-
CTAGTGTCCTCCGCTGTGG-3′) and an antisense primer (5′-AAGGTGTTTTTCCGGCATC-3′) at 5 nM 
final concentration, producing a fragment (62–230 bp) from GenBank Accession no. BC062709. Three 
amplifications follow the same protocol explained by Baiula and collaborators 123. 
Relative expression levels of  RT-PCR products were determined using the ΔΔCt method 124. Each sample 
was tested in triplicate and the mean Ct was used in the ΔΔCt equation as described by Baiula and 
collaborators 125. 
 cAMP measurement  
The secong messenger Adenosine 3’5’ cyclic monophosphate cAMP responses were examinated by using 
Cayman chemical cyclic AMP Elisa kit, according to the manufacturer’s recommendations (Chaymanchem 
Ellsword Rd, Ann Arbor Mi, USA).  
Cyclic AMP Elysa Kit used is based on the competition between free cAMP and cAMP-
acetylcholinesterase (AChE) conjugate (cAMP tracer) for a limited number of cAMP-specific rabbit 
antibody binding sites which bind to the mouse monoclonal anti-rabbit IgG that has been previously 
attached to the well.hen using Hellman’s reagent that contain substrate of (AChE), the plate is measured 
spectrophotometrically at 412 nM where the intensity of colour is proportional to the amount of cAMP 




SHSY5Y native cells were treatment with forskolin an activator of adenylyl cyclase at 10 M for 15 min 
and morphine 1 M fo 15 min or ephrinB1-Fc 1 g/ml for 15 min or both ligands for 15 min, then were 
scraped off in cold phosphate-buffered saline, centrifuged and the pellet homogenised with 0.1M HCl, and 
centrifuged at 10,000g for 15 minutes at 4°C to obtain the supernatant. Then 100 μL of the diluted cAMP 
standard solution was loaded to 96-well plates whereas 50μl of the supernatant obtained above was mixed 
with 50 μL of cAMP tracer and loaded to 96-well plates followed the recommendations of manufacturer’s  
and incubated for 18 hours. All standards and samples were run in duplicate. After the incubation the plates 
were empty and rinse with wash buffer and then treated with Ellman’s reagent for 90 -120 min then 
Ellman’s reagent were removed and measured spectrophotometrically at 420nm. The cAMP values 
obtained from the absorvance measurements were converted by the total protein amount expressed as 
percentage of cAMP. Data analysis was performe as explained in 
https://www.caymanchem.com/pdfs/581001.pdf.  
 Statistical analysis 
In RT-PCR sample was amplified in triplicate; in the other experiments were repeated at least three times. 
All data are presented as mean ± SEM for the number of experiments indicated. Statistical significance was 
determined by Newman–Keuls test after Anova using GraphPad Prism, version 3.0 (GraphPad Software 













In this investigation, I used two different cell models, the first human neuroblastoma cell line SHSY5Y due 
to is the most cell model used in neuroscience and neuroblastoma research 126. These cells express several 
human-specific proteins and protein isoforms that would not be inherently present in rodent primary 
cultures 127,  among them opioid receptors 128 and some tyrosine kinases receptors.  
Previously, Lombardi S in Prof. Spampinato laboratory has evaluated and confirmed the expression of 
EphB1 and MOR receptors in human neuroblastoma cell line SHSY5Y and the presence of an occlusive 
croostalk between both receptor EphB1 and MOR which dependent of the physiological state of neuronal 
cells 121. 
Hence, my reserach was focused in elucidated the downstream molecules and mechanism involved in the 
occlusive interaction, as well as, possible antagonist peptides that could inhibit the croostalk between both 
receptors.  
 Downstream molecules involved in occlusive crosstalk observed 
following the co-administration of morphine and ephrinB1-Fc ligands. 
Previously, it has been explained that  EphB1 agonist (ephrinB1-Fc) and MOR agonist (morphine) receptors 
induce a time-dependent increase of p42/44 phosphorylation only when these ligands are administered as 
single agents whereas their co-administration occluded p42/p44 MAPK activation 121. 
Furthermore, Mu opioid receptors (MOR) eliciting a significant analgesia through different signaling 
events, such as, adenylyl cyclase inhibition and activation of p42/p44 MAPK phosphorylation 113,129 
whereas the activation of ephrinB1/EphB1 system can produce diverse pain states through the activation of 
MAPK mechanism principally by the phosphorylation of p42/44 MAPK  42,59,71. The phosphorylation of 
p42/44 MAPK plays an important role either in analgesia and in pain states being a convergence point for 




Hence, elucidate the signaling pathways involved in p42/44 MAPK modulation ephrinB1-Fc- and 
morphine-mediated in SHSY5Y cells is an important step for explain the appearance of occlusive crosstalk 
after of the co-admistration of MOR and EphB1 ligands.  
 Signaling pathways involved in p42/p44 MAPK activation elicited by ephrinB1 Fc- 
and Morphine in SHSY5Y native cells.   
Inhibitors of several signaling pathways involved in p42/44 MAPK activation were used. Gö6976 (5 μM) 
a PKC inhibitor which only inhibits classical isoforms, PP2 (5 μM) a selective inhibitor of Src-family 
tyrosine kinases and LY294002 (10µM) a reversible competitive PI3K inhibitor were administered before 
ephrinB1-Fc or morphine stimulation.  
SHSY5Y cells starved for 16-18 hours, were pre-treated for 30 min with PKC or Src inhibitors and 60 min 
with PI3K inhibitor before of the stimulation of MOR and EphB1 receptors by morphine (1µM) and Ephrin 
B1-Fc (1µg/mL) ligands respectively for 15 min. By western blots, I have evaluated p42/44 MAPK 
phosphorylation using anti p-p42/44 and anti p42/44 antibodies.  
Thus, I observed that p42/44 MAPK activation EphB1-mediated was not abrogated by the PKC inhibitor 
(Gö6976) and Src inhibitor (PP2) while PI3K inhibitor LY294002 was able to inhibit p42/44 MAPK 
activation. This suggest that p42/p44 MAPK activation by ephrinB1-Fc is PKC- and Src-independent but 
PI3K signaling pathway plays an important role in p42/44 activation. (Figure 13a) 
Conversely, p42/44 MAPK activation MOR-mediated was abrogated by the PKC inhibitor (Gö6976), but 
not by Src inhibitor (PP2) and PI3K inhibitor (LY294002) suggesting that PKC signaling pathway 
contributes in p42/p44 MAPK activation by morphine, whereas Src and PI3K are not involved in this 
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Figure 13: Signaling pathway involved in p42/p44 MAPK activation by ephrinB1-Fc and Morphine. (a) Western blot analysis 
of p42/44 MAPK phosphorylation levels in SHSY5Y native cells treated with Gö6976 (5 mM) or PP2 (5 mM) 30 min and 
LY294002 60 min prior ephrinB1-Fc administration (1µg/ml; 15 min). (b) Western blot analysis of p42/44 MAPK phosphorylation 
levels in SHSY5Y native cells treated with Gö6976 (5 mM) or PP2 (5 mM) 30 min and LY294002 60 min prior morphine 
administration (1µM; 15 min). SHSY5Y native cells were considered as control group. Densitometric analysis of the bands is 
shown (mean ± SEM of five independent experiments); the amount of p42/44 MAPK were normalized to total p42/44 MAPK. 
**=p<0.01 vs vehicle, *=p<0.05 vs vehicle; °°=p<0.01 vs ephrinB1-fc or morphine.  
 
 PI3K signaling pathway is involved in the occlusive croostalk produced by the co-
administration of morphine and ephrinB1-Fc ligands.  
The occlusive croostalk observed by the concomitant administration of both agonist (morphine and 
ephrinB1-Fc) lead to reduce p42/44 MAPK phosphorylation, likely due to the activation of 
ephrinB1/EphB1 system 121. Therefore, blocking the interaction between EphB1 receptor with Ephrin B1 
ligand could restore the principal signaling pathways involved in the analgesic effects produced by MOR 
agonist as morphine.  
Since previously have found that morphine can activate p42/44 MAPK via PKC pathway and that the 





with PKC and PI3K inhibitors to evaluate the effects of both inhibitors in the occlusive croostalk previously 
evidence.  
By western blot analysis I assessed p42/44MAPK proteins expression. SHSY5Y cells starved for 16-18 
hours were pre-treated with PKC inhibitor for 30 min and PI3K inhibitor for 60 min before concomitant 
administration of morphine and ephrinB1-Fc ligands for 15 min. I observed that the co-administration of 
ephrin-B1-Fc and morphine does not show a synergistic effect caused by EphB1- and MOR-activated 
signaling pathways on p42/44 MAPK phosphorylation (Figure 14); thus, confirming previous results.  
Futhermore, the inhibition of PKC signaling pathway by Go6976 inhibitor is not able to abolish the effect 
produced by the co-admistration of both ligands whereas when PI3K signaling pathway was inhibited by 
LY294002 interestengly the occlusive croostalk produced is completely abolished and the effects of 
morphine in the activation of p42/44 MAPK seem to be restored (Figure 14). Thus, suggesting that the 




































































































































Figure 14: Blocking PI3K signaling pathways restores the effects of morphine in the activation of p42/44 MAPK. 
Representative western blots of the modulation p42/44 MAPK phosphorylation in SHSY5Y native cells treated with Gö6976 (5 
mM) 30 min and LY294002 60 min prior to the co-administration of EphrinB1-Fc (1µg/ml; 15min) and morphine (1μM; 15 min). 
Densitometric analysis of the bands are shown (mean ± SEM of sixteen independent experiments); the amount of p42/44 MAPK 
were normalized to total p42/44 MAPK. SHSY5Y native cells were considered as control group. n=16, *** = p<0.001 vs vehicle, 




 Blocking PI3K signaling pathway also can recovers completely the activation of 
PKC protein.  
Morphine can activate p42/44 MAPK phosphorylation via the protein kinase C (PKC)-dependent pathway 
130 regulating Mu opioid receptor signaling 131. 
We explored the involvement of ephrinB1/EphB1 system in the modulation of PKC protein. Thereby, by 
western blot analysis I assessed the changes in PKC phosphorylation when PI3K signaling pathway was 
inhibited.   
SHSY5Y cells starved for 16-18 hours were pre-exposed to LY294002 inhibitor of PI3K pathway 60 min 
before of the treatment with ephrinB1-Fc (1μg/ml) or morphine (1 μM) or with both ligands for 15 min. I 
observed that, as well as p42/44 MAPK phosphorylation is restored when PI3K signaling pathway is 
inhibited, also PKC phosphorylation was totally recovered in comparison to cells co-treated with morphine 
and ephrinB1 ligands (Figure 15), suggesting that the co-activation of EphB1 MOR receptors inhibit the 


















































































































Figure 15: Blocking ephrinB1/EphB1 pathway restored PKC phosphorylation. Representative western blot analysis of PKC 
phosphorylation in SHSY5Y native cells treated with LY294002 60 min prior co-administration of EphrinB1-Fc (1µg/ml; 15min) 
and morphine (1μM; 15 min). Densitometric analysis of the bands is shown (mean ± SEM of three independent experiments); the 
amount of PKC protein was normalized to β-actin protein. SHSY5Y native cells were considered as control group.  n=3, * = p<0.05 








  cAMP expression is involved in antagonist interaction between MOR and EphB1 
receptors.  
I have determinated thereafter, if the activation of ephrinB1/EphB1 system is involved in the block of 
morphine effects on MOR receptors. However, the mechanism by which this block could be produced is 
unknown.  
To assay, one of the possible mechanism contributing to the lack of morphine effects on MOR receptors 
and considering that morphine reduced cAMP levels through the stimulation of Gi protein α-subunit 132 and 
that intracellular cAMP changes are mediated through the modulation of adenylate cyclase activity, I have 
decided to evaluate changes in cAMP content in cells after treatments.  
I used Forskolin an activator of adenylate cyclase enzyme that can generates cAMP from ATP, raising 
intracellular cAMP levels. Thus, as showed in Figure 16, in SHSY5Y native cells forskolin (10μM, 15 min) 
increased the expression of cAMP whereas morphine reduced the forskolin effects. Treatment with 
ephrinB1-Fc does not produce significant changes in cAMP, but interestingly when the cells were co-treated 
with both ligands (morphine and ephrinB1) was produced an increase in the levels of cAMP. This effect 
probably is produced due to morphine does not capable to inhibit adenylate cyclase likely by the activation 

































































































































Figure 16: Inhibition of cAMP accumulation induced by forskolin is involved in occlusive crosstalk produced by the co-
administration of morphine and ephrinB1-Fc ligands. SHSY5Y native cells were treated with forskolin (10μM, 15min) and 
morphine (1μM, 15min) or ephrinB1-Fc (1μg/ml, 15min) or both ligands. cAMP levels were measured using Cayman chemical 
cyclic AMP Elisa kit according to the manufacturer’s recommendations. The results are presented as percentage of inhibition of 
cAMP accumulation. n=3, * = p<0.05 vs vehicle and °= p<0.05 vs morphine.  
 
 
  Occlusive crosstalk in PMA-differentiated SHSY5Y cells. 
 
SHSY5Y cells can be differentiated to mature neuron-like phenotype 127 and for this reason are considered 
a suitable cell model for studying neuronal differentiation 133. In fact depending on media conditions can 
express different phenotypes such as cholinergic or dopaminergic/adrenergic 133. Phorbol 12-myristate 13-
acetate (PMA), a differentiation agent, can stimulated SHSY5Y neuroblastoma cells towards neuronal 
differentiation by blocking cell growth and inducing neurite outgrowth 134,135. 
Lombardi S, previously evaluated the effects of the co-administration of morphine and ephrinB1-Fc in 
PMA-SHSY5Y differentiated cells. She observed that the conconmitant administration of ephrin-B1-Fc 
and morphine ligands no longer occludes p42/p44 MAPK activation 121. Furthermore, cell differentiation 
produced changes in mRNA and protein levels of MOR and EphB1 receptors, the levels of Mor receptors 
were increased in comparison to SHSY5Y native cells whereas the levels of EphB1 receptors either in 




Hence, in agreement whith this previous research and considering that in SHSY5Y native cells the 
inhibition of PI3K pathway lead to restore p42/44 MAPK and PKC phosphorylation morphine-mediated I 
decided to investigate the effect of inhibit PI3K pathway after differentiation with PMA for five days.  
 Blocking PI3K signaling pathway in PMA-differentiated SHSY5Y cells does not 
affect p42/44 and PKC phosphorylation.   
After differentiation with PMA (16nM) for 5 days, SHSY5Y- differentiated cells were starved for 16-18 
hours in serum free medium and then exposed to ephrinB1-Fc (1μg/ml) or morphine (1 μM), or both ligands 
for 15 min and pre-exposed to LY294002 inhibitor of PI3K pathway 60 min before of the treatment with 
ephrinB1-Fc (1μg/ml) or morphine (1 μM) for 15 min.  
By western blot analysis of p42/44 MAPK and PKC proteins, I observed that p42/44 MAPK 
phosphorylation was increased by co-treatment with both ligands which could be due to high transcription 
and protein expression of MOR receptors and low expression of EphB1 receptors (Figure 17a), confirming 
the results observed by Lombardi, S, as the administration of ephrinB1-Fc to PMA-differentiated SHSY5Y 
cells no longer occludes morphine-mediated activation of p42/p44 MAPK phosphorylation. 
Besides, blocking PKC and PI3K pathways under co-administration of both ligands it was showed that the 
inhibition of PKC pathway does not allow full activation of MOR receptor; obviously, MOR activation is 
PKC-dependent whereas inhibition of PI3K pathway does not alter the normal activation of p42/44 MAPK 
phosphorylation by morphine (Figure 17a) since as I have described before the lower expression of EphB1 
receptor is not able to block MOR activation.  
A similar trend was observed by western blots of PKC phosphorylation (Figure 17b), where the 
downregulation of EphB1 receptor following the inhibition PI3K pathway does not modificate MOR 
activation after the co-administration of morphine and ephrinB1-Fc ligands, thus,  allowing me to think that 























































































































































































































































Figure 17: p42/44 MAPK and PKC phosphorylation are not altered by the co-administration of morphine and ephrinB1-
Fc ligands. a) Representative western blot analysis of p42/44 MAPK phosphorylation in PMA-differentiated SHSY5Y cells treated 
with ephrinB1-Fc (1μg/ml) or morphine (1 μM), or both ligands for 15 min and pre-exposed to Gö6976 (5 mM) 30 min and 
LY294002 60 min to the co-administration of EphrinB1-Fc (1µg/ml and morphine (1μM) for 15 min  b) Western blot analysis of 
PKC phosphorylation in PMA-differentiated SHSY5Y cells treated with ephrinB1-Fc (1μg/ml) or morphine (1 μM), or both ligands 
for 15 min and pre-exposed to LY294002 60 min prior to the co-administration of EphrinB1-Fc (1µg/ml; 15min) and morphine 
(1μM; 15 min). Densitometric analysis of the bands is shown (mean ± SEM of six independent experiments); the amount of p42/44 
MAPK were normalized to total p42/44 MAPK whereas the mounts of PKC protein were normalized to β-actin protein.  PMA- 
differentiated SHSY5Y cells were considered as control group n=6, ***= p<0.001 vs vehicle, ** = p<0.01 vs vehicle, * = p<0.05 
vs vehicle and °°= p<0.01 vs morphine.  
 
  Occlusive crosstalk in PMA-differentiated SHSY5Y cells exposed to a 
pro-inflammatory stimulus 
So far, I have observed that the concomitant activation of EphB1 and MOR receptor block p42/44 MAPK 
and PKC activation in SHSY5Y native cells. However, the inhibition of a main signaling pathway involved 
in the EphB1 receptor activation can abolish the block of the activation of MAPK and PKC 
phosphorylation. Since SHSY5Y native cells can be exposed to a differentiating stimulus in a celular model 
resembling mature neurons in vivo and that under this condition the activation of EphB1 receptor is not 





SHSY5Y cells by the administering tumor necrosis factor (TNF-α), a proinflammatory stimulus, which 
play a key role in development of central sensitization and persistence pain 117,136. 
 
 MOR and EphB1 expression is altered in PMA-Differentiated SHSY5Y cells 
exposed to TNFα.  
In order to assess any significant change in mRNA and protein levels of EphB1 and MOR receptors in 
PMA-differentiated SHSY5Y, cells were exposed to pro-inflammatory stimuli for mimicking the 
neuroinflammatory response that contributes to different persistence pain states among them neuropathic 
pain.  
For this reason, SHSH5Y cells during the last 48 h of differentiation were treated with TNF-α at 
concentration of 10 ng/ml. Then the expression of EphB1 and MOR transcripts were measured by Real 
time PCR (as explained in materials and methods) whereas protein levels of EphB1 and MOR were 
analyzed by western blot and saturation binding assay, respectively. 
I observed that, the exposure of TNF-α (10 ng/mL) to PMA-differentiated SHSY5Y cells produces the 
alteration of EphB1 and MOR receptors in comparison to SHSY5Y native cells and differentiated SHSY5Y 
cells.   
As regards, EphB1 receptors it was observed that the exposure of TNF-α up-regulate dramatically the levels 
of mRNA and protein in comparison to control cells (Figure 18a, 18b).  
Whereas, transcript Mor levels were more up-regulated in comparison to SHSY5Y native and differentiated 
cells and their protein levels present the same trend of increase that in PMA-differentiated cells (Figure 
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Figure 18: Exposition to TNF-α produced changes in  EphB1 receptor and MOR expression in PMA-differentiated SHSY5Y 
cells a) Real-time PCR of EphB1 in PMA- differentiated SHSY5Y cells exposed to TNF-α, mRNA levels of EphB1 receptor were 
significantly increased in comparison with SHSY5Y native cells and PMA – differentiated SHSY5Y cells b) EphB1 protein levels 
present the same pattern c) mRNA levels of MOR receptors are significantly increased d) while MOR protein levels present the 
same pattern that PMA-differentiated cells. mRNA levels of EphB1 and MOR were calculated using the ΔΔCt method as described 
in materials and methods. For protein levels of EphB1 was performed a densitometric analysis of the bands and the amount of 
EphB1 receptors were normalized to β-actin. For MOR protein levels was performed a Saturation binding assays which were 
conducted using [3H] DAMGO on cell membranes, a single-site receptor binding model provided the best fit for data analysis, 
Bmax values were estimated from non-linear regression analysis. Values are mean ± SEM of at least six independent experiments. 
SHSY5Y native cells were considered as control group *** = p<0.001, ** = p<0.01, * = p< 0.05 vs undifferentiated cells; ° = p< 












 Occlusive crosstalk occurs in PMA-differentiated SHSY5Y cells exposed to TNF-α. 
Previously, I have seen that exposition of SHSY5Y- differentiated cells to pro-inflammatory stimuli as 
TNF-α, has altered the expression of EphB1 and MOR receptors, mainlly EphB1 expression was 
dramatically up-regulated in comparison to SHSY5Y undifferentiate and differentiate cells.  
To evaluate, if the occlusive croosstalk could be restored since EphB1 receptors expression are more up-
regulated in comparison that SHSY5Y native cells, SHSY5Y- differentiated cells exposed to TNF-α were 
starved for 16-18 hours and then treated with ephrinB1-Fc (1μg/ml) or morphine (1 μM), or both ligands 
for 15 min.  
By western blots analysis, I observed that the co-administration of both ligands led to restore the occlusive 
crosstalk in p42/44 MAPK activation (Figure 19), due to the high EphB1 receptors expression, thus, 
confirming once again that ephrinB1/EphB1 system activation is involved in p42/44 MAPK inhibition 





































































































Figure 19. Ephrin B1 Fc– mediated occlusion on p42/p44 MAPK phosphorylation is restored, in PMA-differentiated 
SHSY5Y cells exposed to TNF – α. Western blot analysis of p42/44 MAPK phosphorylation levels in PMA-differentiated 
SHSY5Y cells exposed to TNF-α, un-treated or treated with morphine (1μM; 15 min) EphrinB1-Fc (1µg/ml; 15min), or co-treated 
with both EphrinB1-Fc (1µg/ml; 15min) and morphine (1μM; 15 min). PMA-SHSY5Y cells exposed to TNF-α were considered 
as control cells. Densitometric analysis of the bands is shown (mean ± SEM of four independent experiments); the amount of 




 TNF-α added to PMA-differentiated SHSY5Y cells blocks the signaling pathway 
involved in ephrinB1/EphB1 system activation and recues p42/44 MAPK and PKC 
activation produced by morphine.  
Previously, I have seen that the exposition of PMA-differentiated cells to TNF-α restored the antagonist 
interaction between MOR and EphB1 receptors as those in native SHSY5Y cells.  
I decided to employ PMA-differentiated SHSY5Y exposed to TNF-α cells for evaluate if the inhibition of 
PI3K pathway may also to restore p42/44 MAPK and PKC phosphorylation.  
To this aim, SHSY5Y differentiated cells exposed to TNF-α were starved for 16-18 hours and pre-treated 
whith PI3K inhibitor for 60 min before of the concomitant administration of morphine and ephrinB1-Fc 
ligands for 15 min. Then I assessed the modulation of p42/44MAPK and PKC proteins by western blot 
analysis. 
I observed that likewise in SHSY5Y native cells, blocking the signaling pathway responsible of EphB1 
activation allowed the complete activation of p42/44 MAPK (Figure 20a) and PKC proteins (Figure 20b) 















































































































































































































































Figure 20. Blocking PI3K pathway in PMA-differentiated SHSY5Y cells exposed to TNF – α the normal activation of p42/44 
MAPK and PKC proteins were restored. a) Western blot analysis of p42/44 MAPK phosphorylation levels in PMA-
differentiated SH-SY5Y human neuroblastoma cells exposed to TNF-α, treated with morphine (1μM; 15 min) or EphrinB1-Fc 
(1µg/ml; 15min), or co-treated with both EphrinB1-Fc (1µg/ml; 15min) and morphine (1μM; 15 min) and pre-exposed to 
LY294002 60 min  to the co-administration of EphrinB1-Fc (1µg/ml; 15min) and morphine (1μM; 15 min)  b) Western blot analysis 
of PKC phosphorylation in PMA-differentiated SHSY5Y cells exposed to TNF-α treated with ephrinB1-Fc (1μg/ml) or morphine 
(1 μM) , or both ligands for 15 min and pre-exposed to LY294002 60 min prior to the co-administration of EphrinB1-Fc (1µg/ml; 
15min) and morphine (1μM; 15 min). Densitometric analysis of the bands is shown (mean ± SEM of four independent experiments); 
the amount of p42/44 MAPK were normalized to total p42/44 MAPK whereas the mounts of PKC protein were normalized to β-
actin protein.  PMA- differentiated SHSY5Y cells exposed to TNF- α were considered as control group. n=4, ***= p<0.001 vs 
vehicle, ** = p<0.01 vs vehicle, * = p<0.05 vs vehicle and °= p<0.05 vs morphine.  
 
 
 Blockade of EphB1 receptor activation by novel peptide antagonist 
So far, we have observed that the inhibition of signaling pathways involved in EphB1 receptor activation 
ephrinB1-Fc-mediated restored morphine effects on MOR receptors.  
Several studies have demonstrated that EphrinBs/EphBs signaling pathway is a key regulator of physiologic 
and pathologic processes underlying pain and other CNS diseases; thus, suggesting that may act as a new 
molecular target for pain prevention and relief 70. Particularly, it has been demonstrated that reducing EphB1 





pain in rodent models suggesting that antagonist targeting EphB1 receptor could represent a novel class of 
analgesics for the treatment of difficult-control chronic pain 32.  
In this context, the development of agents that bind to the extracellular ephrin-binding pocket of these 
receptors show promise for medical applications. Koolper and collaborators through phage display found 
different sequence of peptides which have the capacity to bind EphB receptors selectively. I selected 
EWLSPNLAPSVR linear sequence, because present 100% specificity to EpB1 receptor 95, and from this 
linear sequence, four different sequence of linear peptide were synthetized by Profesor Alessandra 
Tolomelli at the Department of Chemistry of the University of Bologna. These peptides were characterized 
by evaluating their ability to modulate EphB1 receptor either as a single agent or with the previous 
administration of EphB1 agonist (ephrinB1-Fc).   
Considering that the activation of p42/44 MAPK in response to EphB1 stimulation is involved in several 
pathological processes, I retained important firstly, to assay the ability of these peptides to modulate p42/44 
MAPK phosphorylation by itself and to counteract ephrin B1-Fc-mediated activation.  
For tested these peptides I used human embryonic kidney cell line (HEK-293) due to has been greatly used 
as an expression tool for recombinant protein and also for its incredible use in stably transfected forms to 
study a variety of cell-biological questions in neurobiology  137. 
 
 Administration of EphB1 binding peptides in HEK-EphB1 cells do not activate 
p42/44 MAPK activation.   
I tested four different linear sequence peptides EWL or Tripeptide, SPNLA or Pentapeptide, EWLSPN or 
Hexapeptide and EWSPNLA or Octapeptide.  
HEK-EphB1 stably transfected cells were plated in 6-well dishes until 50–60% of confluence and then 
starved of serum for 16-18 hours and treated for 15 min with different concentrations of each peptide.  
I observed that none of these compounds have the capacity to activate or inhibit p42/44 MAPK 





























V e h ic le
T r ip e p tid e  (1 0  n m , 1 5  m in )
T r ip e p tid e  (1 0 0  n m , 1 5  m in )
T r ip e p tid e  (1  µ m , 1 5  m in )
T r ip e p tid e  (1 0  µ m , 1 5  m in )

























V e h ic le
P e n ta p e p tid e  (1 n M ; 1 5 m in )
P e n ta p e p tid e  (1 0  n M ; 1 5  m in )
P e n ta p e p tid e  (2 0  n M ; 1 5  m in )
P e n ta p e p tid e  (1 0 0  n M ; 1 5  m in )

























V e h ic le
H e x a p e p tid e  (1 n M ; 1 5 m in )
H e x a p e p tid e  (1 0  n M ; 1 5  m in )
H e x a p e p tid e  (2 0  n M ; 1 5  m in )
H e x a p e p tid e  (1 0 0  n M ; 1 5  m in )
H e x a p e p tid e  (1 M ; 1 5  m in )
H e x a p e p tid e  (1 0 M ; 1 5  m in )

























V e h ic le
O c ta p e p tid e  (0 ,1  n m ; 1 5  m in )
O c ta p e p tid e  (1  n m ; 1 5  m in )
O c ta p e p tid e  (1 0  n m ;1 5  m in )
O c ta p e p tid e  (1 0 0  n m ; 1 5  m in )
O c ta p e p tid e  (1  µ m ; 1 5  m in )
O c ta p e p tid e  (1 0  µ m ; 1 5  m in )
O c ta p e p tid e  (1 0 0  µ m ;1 5  m in )
 
Figure 21. Effects of the different linear peptides on p42/44 MAPK phosphorylation when are administered as a single agent 
in HEK-EphB1 cells. Representative Western blot analysis of the effects of four different linear peptides in p42/44 MAPK 
phosphorylation levels. HEK-EphB1 cells treated for 15 min with different concentration of a) EWL tripeptide, b) SPNLA 
pentapeptide, c) EWLSPN hexapeptide, d) EWLPNLA octapeptide. HEK-EphB1 cells were considered as control cells. 
Densitometric analysis of the bands is shown (mean ± SEM of four independent experiments); the amount of p42/44 MAPK were 












 Effects of Tripeptide and pentapeptide on p42/44 MAPK phosphorylation mediated 
by ephrinB1-Fc in HEK-EphB1 cells.  
Previuos studies have demonstrated that EphrinB1-Fc induced hyperalgesia accompanied by activation of 
MAPKs (mitogen-activated protein kinases -dependent), mainly p42/44 MAPK proteins,58,71 and that 
previously Lombardi Sara has observed that the exposure for 15 min of HEK-EphB1 cells to Ephrin B1 Fc 
(1μg/ml) produce a great activation of p42/44 MAPK 121. I evaluated if the first two peptides synthesized 
possess the ability to counteract the effect of ephrinB1-Fc in the p42/44 MAPK phosphorylation.  
HEK-EphB1 stably transfected cells were plated in 6-well dishes until 50–60% of confluence and then 
starved of serum for 16-18 hours and pre-treated for 15 min with different concentration of tripeptide and 
pentapeptide and then treated with ephrinB1-Fc (1μg/ml) for 15 min.  
By western blot, the effects of both peptides in the modulation of p42/44MAPK phosphorylation were 
evaluated.  
I have observed in both cases an increase in the phosphorylation of p42/44 MAPK due to the effect of 
ephrinB1-Fc, in other words tripeptide (Figure 21a) and pentapeptide (Figure 21b) did not counteract 
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Figure 21. Effects of tripeptide and pentapeptide on p42/44 MAPK phosphorylation mediated by EphrinB1-Fc in HEK-
EphB1 cells. Representative Western blot analysis of p42/44 MAPK phosphorylation levels HEK-EphB1 cells treated or untreated 
with ephrinB1-fc (1μg/ml) for 15 min and differenten concentration of a) Tripeptide, b) Pentapeptide for 15 min. HEK-EphB1 
cells were considered as control cells. Densitometric analysis of the bands is shown (mean ± SEM of three independent 
experiments); the amount of p42/44 MAPK were normalized to total p42/44 MAPK. n=3. ***= p<0.001 vs vehicle, ** = p<0.01 
vs vehicle, * = p<0.05 vs vehicle.   
 
 Effects of hexapeptide on p42/44 MAPK phosphorylation mediated by ephrinB1-
Fc in HEK-EphB1 cells  
The peptide sequence of the hexapeptide is derivative from EWLSPNLAPSVR which selectively can 
inhibit EphB1 receptor with IC50 of 10μM 95. By using HEK-EphB1 cells, I evaluated if this peptide may 
modulate ephrinB1-Fc-mediated p42/44 MAPK phosphorylation.  
Cells were pre-incubated for 15 min with various concentrations of hexapeptide and then treated with 
ephrinB1-Fc at 1μg/mL for further 15 min to activate EphB1 receptor (Figure 22a). By western blot 
analysis, I observed that hexapeptide inhibits p42/44 MAPK phosphorylation ephrinB1-Fc-mediated at 
higher concentration. Indeed, hexapeptide can counteract ephrinB1-Fc-mediated activation of p42/44 
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Figure 22. Effects of hexapeptide on p42/44 MAPK phosphorylation mediated by EphrinB1-Fc in HEK-EphB1 cells. a) 
Representative Western blot analysis of p42/44 MAPK phosphorylation levels, cells were pre-treated with ephrinB1-Fc (1µg/ml; 
15 min) with or without different concentration of hexapeptide for 15 min. HEK-EphB1 cells were considered as control, b) IC50 
value for hexapeptide. Densitometric analysis of the bands is shown (mean ± SEM of seven independent experiments); the amount 
of p42/44 MAPK were normalized to total p42/44 MAPK. n=7. ***= p<0.001 vs vehicle, * = p<0.05 vs vehicle and °° = p<0.01 
vs ephrinB1. 
 
 Effects of octapeptide on p42/44 MAPK phosphorylation mediated by ephrinB1-Fc 
in HEK-EphB1 cells. 
Previously, I observed that tripeptide and pentapeptide does not inhibit the effects of ephrinB1-Fc in p42/44 
MAPK phosphorylation whereas that hexapeptide at a 1,21 μM of concentration inhibits this activation. 
Then, I decided to assay larger peptide than hexapeptide named octapeptide.  
HEK-EphB1 cells were subjected to dose-response experiments in which cells were incubated for 15 min 
to various concentration of octapeptide and treated for 15 min with ephrinB1- Fc (1 μg/mL) to monitor the 
possible antagonistic activity of the peptide.  
By western blot analysis, I observed that p42/44 MAPK phosphorylation decreases whenever the peptide 
concentraction increases (Figure 23a) demonstrating that effectively longer peptide is more potent 
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Figure 23. Effects of octapeptide on p42/44 MAPK phosphorylation mediated by EphrinB1-Fc in HEK-EphB1 cells. a) 
Representative Western blot analysis of p42/44 MAPK phosphorylation levels, cells were pre-treated with ephrinB1-Fc (1µg/ml; 
15 min) with or without different concentration of octapeptide for 15 min. HEK-EphB1 cells were considered as control cells b) 
IC50 value for hexapeptide. Densitometric analysis of the bands is shown (mean ± SEM of four independent experiments); the 
amount of p42/44 MAPK were normalized to total p42/44 MAPK. n=4. **= p<0.01 vs vehicle, * = p<0.05 vs vehicle and ° = 
























This investigation report for the first-time evidence that support the involvement of EphB1 
receptor signaling in an occlusive crosstalk with mu opioid receptors (MOR), which could be 
implicated in the ineffectiveness of analgesic effects morphine-mediated as well as in the onset 
and maintenance of different chronic pain states and in the development of dependence and 
tolerance to opioids.  Furthermore, I have found two possible EphB1 receptor peptide antagonists 
which may provide a novel strategy to reduce the negative impact of ephrin system activation on 
pain perception and opioid efficacy.  
EphB/ephrinB system possess the capacity to produce bidirectional signals either pre- or 
postsynaptically, activating a wide variety of signal transduction pathways138 which through 
neuron-glia communication 60,59,62 can communicate with a variety of other cell surface proteins. 
In the mature nervous system, the upregulation of ephrinB and EphB1 receptor in nociceptive 
dorsal root ganglion (DRG) neurons and in spinal dorsal horn (DH) neurons after nerve injury and 
bone cancer, as well as after the long exposure to opiates, have been involved in various types of 
pain; even to those accompanied by long-lasting alterations of the excitability of spinal neurons, 
69,65,67 and in physical dependence and tolerance to opiates respectively 70.   
Activation of EphB1 receptors by ephrinB1-Fc ligand produce a dose- and time-dependent thermal 
and mechanical hyperalgesia, accompanied by the increased activation of PI3K 61 and mitogen-
activated protein kinases (MAPKs), particularly p42/p44 MAPK 59. Spontaneous pain, thermal 
hyperalgesia, mechanical allodynia, and opiate tolerance were inhibited using EphB1 blockers, 
suggesting that antagonist targeting EphB1 receptor could represent a novel class of analgesics for 
the treatment of painful neuropathies 32.  
Opioid receptors are members of the G protein-coupled receptor (GPCR) family, being the mu 
opioid receptor (MOR) the most important relevant. Opioid receptors can be activated by both 
endogenous and exogenous opioids in central and peripheral nervous system 113. Morphine and 
related MOR agonists are among the most widely used pain killers which produce analgesia trough 
the inhibition of adenylyl cyclase activity 113 and activation of p42/p44 MAPK phosphorylation 
114. However, chronic exposure to opioids may result in different relevant side effects (tolerance, 




There some studies that demonstrate evidence tahta G protein-coupled receptors (GPCRs) and 
receptor tyrosine kinases (RTKs) can cross-communicate each other and activate overlapping 
signaling pathways. For instance, the functional interactions between the EGF receptor (tyrosine 
kinase receptor) and dopamine D2-like receptors (G protein-coupled receptor ) where the signaling 
of D3R is selectively inhibited by EGFR stimulation 139 
Therefore, considering that EphB receptor activation produce hyperalgesia through the activation 
of p42/p44 MAPK whereas morphine by the activation of p42/p44 MAPK produce their analgesic 
effects, the presence of a potential inverse relation between the activation of the EphB-ephrinB 
system and the analgesic effects produced by MOR agonists was studied. 
This investigation was previously initiated at University of Bologna by Lombardi Sara, who found 
a potential cross-talk between EphB1 and MOR. She observed that the activation of EphB1 and 
MOR receptors by their agonists ephrinB1-Fc and morphine respectively in undifferentiated 
SHSY5Y cells induced a time-dependent increase p42/44 MAPK phosphorylation whereas their 
co-administration occluded p42/p44 MAPK activation, suggesting that EphB receptor activation 
by ephrinB1 could prevent the contemporary activation of MOR-mediated intracellular signaling 
pathways. Such crosstalk, as well as EphB1 and MOR expression, were modified in neuronal cells 
underwent to in vitro differentiation and under these conditions the occlusive interaction observed 
disappear and morphine can produce p42/44 MAPK phosphorylation 121.  
These previous data allow me to continue this investigation and confirm that EphB1 receptor 
activation is involved in the reduced effects elicited by morphine as well as I elucidated any 
signaling pathways and mechanism responsible for the functional crosstalk between EphB1 and 
MOR receptors.  
Therefore, the principal findings of this research are the following:  
• MOR activation by morphine is blunted when EphB1 receptor is simultaneously engaged 
by ephrinB1. 
• The p42/44 MAPK phosphorylation ephrinB1-Fc-mediated activation is PI3K- dependent. 
• Inhibition of PI3K signaling pathway EphB1-mediated may rescue morphine-dependent 
intracellular signaling. 
• The occlusive crosstalk triggered by EphB1 receptor activation could be also determined 




• In differentiated neuronal cells, blocking PI3K signaling pathway does not affect p42/44 
and PKC phosphorylation. 
• Differentiated neuronal cells exposed to TNF-α moderately up-regulate MOR and 
dramatically up-regulate EphB1 receptor expression. Under these conditions, p42/44 
MAPK phosphorylation is due to only EphB1 activation and the occlusive crosstalk is 
restored. 
• Blocking signaling pathway involved in ephrinB1/EphB1 system activation in 
differentiated neuronal cells exposed to TNF-α, recover p42/44 MAPK activation 
morphine-mediated. 
• Hexapeptide and octapeptide tested in HEK-EphB1 cells can counteract ephrinB1-Fc-
mediated activation of p42/44 MAPK phosphorylation. These peptides seem to be an 
EphB1 receptor antagonist with an IC50 of 1.21 µM and 0.8 µM. 
Agonist of EphBs and MOR receptors induces the activation of several downstream intracellular 
signaling system, including p42/44 MAPK phosphorylation which play important roles in neuronal 
function 140. Phosphatidylinositol 3- kinase (PI3K), protein kinase A (PKA) act as the downstream 
factors of ephrinB-EphB signaling which are required for p42/44 MAPK activation 61,141 (Figure 
24a), whereas morphine can regulate Mu opioid receptor signaling through the activation p42/44 
MAPK phosphorylation using as downstream molecule protein kinase C (PKC) 131,130 (Figure 24b) 
and in addition via the modulation of intracellular level of adenylate cyclase activity cAMP-
dependent, in normal conditions morphine can reduce cAMP levels through the stimulation of Gi 









   
Figure 24. a) activation of EphB1 receptor by ephrinB1-Fc trigger the phosphorylation of p42/44 MAPK using as a downstream 
signaling pathway PI3K proteins. b) morphine produces their analgesic effects via phosphorylation of PKC and p42/44 MAPK 
proteins and reducing cAMP levels.  
 
The occlusive crosstalk observed by the concomitant administration of both agonists (morphine 
and ephrinB1-Fc) lead to reduced p42/44 MAPK phosphorylation morphine-mediated, likely due 
to the activation of ephrinB1/EphB1 system121. Considering that the activation of EphB1 receptor 
by EphrinB1-Fc is PI3K- dependent, the block of the signaling pathway involved in EphB1 
receptor signaling restore the analgesic effects produced by morphine (Figure 25). Furthermore, 
the inhibition of AC (Adenylyl cyclase) mediated by morphine is prevented if EphB1 is 
simultaneously activated by ephrin, suggesting that EphB1 receptor signaling through the 
activation of PI3K pathway which in turn block morphine effect on cAMP levels hamper the 
induction of opioid mediated intracellular signaling (Figure 25).    
 
Figure 25. Co-administration of ephrinB1-Fc and morphine ligands occludes p42/p44 MAPK activation which is produced by the 
activation of PI3K downstream signaling pathway responsible of the activation of EphB1 receptor signaling. Once that PI3K 
signaling pathway is activated EphB1 receptor can interact with MOR receptors via the modulation of cAMP levels. Dashed lines 
demonstrate that under EphB1 activation morphine does not produce the activation of p42/44MAPK as well as loses the capacity 





Phorbol 12-myristate 13-acetate (PMA) can stimulated SHSY5Y neuroblastoma cells to neuronal 
differentiation converting cells to mature neuron-like phenotype 134,127. Under this condition 
EphB1 and MOR receptors protein and mRNA levels undergo changes in their expression, 
particularly, EphB1 receptor is dramatically down-regulated and in these conditions EphrinB1-Fc 
administration no longer occludes morphine-mediated activation of PKC and p42/p44 MAPK 
phosphorylation (Figure 26).  
 
Figure 26. Co-administration of morphine and ephrinB1-Fc ligands in differentiate neuronal cells does no produce p42/44 MAPK 
and PKC phosphorylation alterations.  
 
Administration of pro-inflammatory stimuli as TNF-α for mimicking the neuroinflammatory 
response that contributes to different persistent pain states in differentiated neuronal cells 
determined a significant increase in protein and mRNA levels of EphB1 receptor; under these 
conditions EphrinB1 Fc– mediated occlusion on p42/p44 MAPK phosphorylation is promptly 
restored. Such crosstalk was abolished blocking the signaling pathway responsible of EphB1 
activation, allowing the complete activation of p42/44 MAPK and PKC proteins (Figure 27) which 
are important downstream proteins involved in analgesics effects of morphine, suggesting that 
EphB1 signaling activation is involved completely in the block of morphine effects which depend 






Figure 27. Exposition of differentiated neuronal cells to TNF-α increase the expression of EphB1 receptor and under these 
conditions restore the antagonist interaction between Mor and EphB1 receptors. Dashed lines show that activation of signaling 
pathway responsible of EphB1 activation block the activation of p42/44 MAPK and PKC activation morphine-mediated.  
At these regards, the two novel EphB1 receptor peptide antagonists tested in this research can 
counteract ephrinB1-Fc-mediated activation of p42/44 MAPK, suggesting that hexapeptide and 
octapeptide are novel EphB1 receptor antagonists and could provide a novel strategy to reduce the 
negative impact of ephrin system activation on pain perception and opioid efficacy. 
Considering that EphB receptors 62,56 and opiate system 87 can modulate NMDA receptor function, 
further studies are needed to determinate if EphB1 receptor activation is directly involved 
ineffectiveness of analgesic effects morphine-mediated or maybe is necessary NMDA receptor 
activation to produce these effects, in addition tested the capacity of the two novel EphB1 
antagonist peptides to counteract ephrinB1-induced attenuation of MOR-dependent signaling in 
neuronal cells co-expressing MOR and EphB1 receptors is necessary to confirm that effectively 














• Activation of EphB1 receptor does not allow that morphine to trigger PKC-dependent 
signaling events downstream of MOR receptor. 
• Morphine administered as single agent inhibit adenylyl cyclase and induce PKC-dependent 
p42/44 MAPK phosphorylation in neuronal cells co-expressing MOR and EphB1 receptor, 
regardless the differentiation or inflammatory state. 
• EphB1 activation by ephrinB1 ligands is PI3K-dependent which is capable to blunt the 
MOR-dependent signaling induced by morphine in undifferentiated neuronal cells, as well 
as in differentiated cells subsequently exposed to pro-inflammatory stimuli, due to the 
expression of MOR and EphB1 receptor are at similar levels. 
• Morphine triggers MOR-dependent signaling in differentiated neuronal cells regardless the 
co-administration of ephrinB1, due to the significant EphB1 receptor down-regulation and 
MOR up-regulation. 
• The two novel Hexapeptide and Octapeptide assayed in this study, may represent two 
potential novel EphB1 receptor peptide antagonists as they effectively counteracted 
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